Enzymatic synthesis of 4 '-ethynyl nucleoside analogs
By using an enzymatic synthesis method and a combination of engineered enzymes, the problems of numerous steps and poor stereoselectivity in the synthesis of existing 4'-ethynyl nucleoside analogs have been solved, and the efficient synthesis of EFdA anti-HIV drugs has been achieved.
Patent Information
- Application Number
- CN202410958399.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-22
- Filing Date
- 2019-07-02
- Publication Date
- 2024-11-22
AI Technical Summary
Existing methods for synthesizing 4'-ethynyl nucleoside analogs involve numerous steps, use many protecting groups, have poor stereoselectivity, and require the use of toxic substances, making it difficult to efficiently synthesize the anti-HIV drug EFdA.
By employing a combination of engineered enzymes such as pentose phosphate mutase (PPM), purine nucleoside phosphorylase (PNP), and deoxyribose phosphorylalloses (DERA), 4'-ethynyl-2'-deoxynucleosides are synthesized in a one-pot process, avoiding the use of protecting groups and improving stereoselectivity.
The synthesis steps were simplified, the stereoselectivity was improved, the use of toxic substances was reduced, and the efficient synthesis of 4'-ethynyl-2'-deoxynucleoside analogs such as EFdA was achieved.
Smart Images

Figure BDA0004949561750000011 
Figure BDA0004949561750000021 
Figure BDA0004949561750000051
Abstract
Description
[0001] This application is a divisional application of an invention patent application with an application date of July 2, 2019, application number 201980058723.8, and invention name “Enzymatic Synthesis of 4'-Ethynyl Nucleoside Analogs”.
[0002] References to electronically submitted sequence listings
[0003] The sequence listing of the present application is electronically submitted via EFS-Web in an ASCII formatted sequence listing, with a file name of "24608WOPCT-SEQLIST-02JU12019.txt", a creation date of July 2, 2019, and a size of 80.5 kb. This sequence listing submitted via EFS-Web is part of the specification and is incorporated herein by reference in its entirety. Background of the Invention
[0005] 4'-Ethynyl-2'-deoxynucleoside analogs are known to have activity against HIV, AIDS and related diseases.
[0006]
[0007] An example of a 4'-ethynyl nucleoside analog is 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA, also known as MK-8591), which is a nucleoside reverse transcriptase translocation inhibitor that has been shown to inhibit mitochondriatic activity in vitro (Kawamoto, A., Kodama, E., Sarafianos SF et al., Int. J. Biochem. Cell Biol.; 40(11): 2410-20
[2008] ; Ohrui, H., Kohgo, S., Hayakawa, H. et al., Nucleosides, Nucleotides & Nucleic Acids, 26, 1543-1546
[2007] ) and in vivo (Hattori, S., Ide, K., Nakata, H. et al., Antimicrobial. Agents and Chemotherapy, 53, 3887-3893
[2009] ) blocks HIV-1 and SIV viral replication. EFdA is claimed in U.S. Patent No. 7,339,053 (referred to as 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine in the '053 patent). EFdA has the following chemical structure:
[0008]
[0009] EFdA is metabolized in cells to its active triphosphate anabolic metabolite, which inhibits HIV reverse transcriptase. In contrast to nucleoside reverse transcriptase inhibitors (NsRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) currently available for the treatment of HIV infection, which lack a 3'-OH group to prevent the incorporation of incoming nucleotides, EFdA retains the 3'OH group and acts as a chain terminator by preventing primer:template translocation in the reverse transcriptase (RT) active site and preventing the incorporation of incoming deoxyribonucleotide triphosphates (dNTPs). Additionally, it is believed that the wrinkling of the modified ribose ring of EFdA contributes to the inhibition of reverse transcriptase by placing the 3'-OH in the carrier, where phosphate transfer from incoming nucleotides is ineffective. (Michailidis E, et al., Mechanism of HIV-1 reverse transcriptase by 4'-ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, J Biol Chem 284:35681–35691
[2009] ; Michailidis E, et al., 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms, J Biol Chem 289:24533–24548
[2014] ).
[0010] In an in vitro HIV replication test, EFdA is an effective antiretroviral and exhibits considerable antiviral activity against clinical isolates of all subtypes evaluated. In vitro, it is rapidly anabolic and metabolized to active triphosphate in both lymphoid cell lines and peripheral blood mononuclear cells, and the intracellular half-life of EFdA triphosphate (EFdA-TP) exceeds 72 hrs. (Stoddart, CA, Galkina, et al., Oral Administration of the Nucleoside EFdA (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque, Antimicrob Agents Chemother, 2015 Jul; 59 (7): 4190–4198, published online on May 4, 2015).
[0011] EFdA has been shown to be effective in animal models of HIV infection, including a humanized mouse model and a rhesus monkey model of SIV infection. Pharmacokinetic studies of oral administration of EFdA in mice and rhesus monkeys showed rapid absorption and high plasma concentrations. The fact that peripheral blood mononuclear cells isolated from rhesus monkeys were difficult to be infected with SIV 24 hours after drug administration demonstrates the long intracellular half-life. (Ibid.)
[0012] Previous syntheses of 4'-ethynyl nucleoside analogs, including EFdA, have modest stereoselectivity in the CN bond formation between the ethynyl-deoxyribose sugar and the 2-fluoroadenine (also known as 2-fluoro-9H-purin-6-amine) nucleobase. Previous syntheses also required protecting groups for the glycosylation reaction, which reduced the efficiency of the synthesis.
[0013] Kei Fukuyama, et al., Synthesis of EFdA via a Diastereoselective Aldol Reaction of a Protected 3-Keto Furanose, Organic Letters 2015, 17 (4), pp. 828-831; DOI: 10.1021 / ol5036535) is a 14-step synthesis from D-glucose diacetonate, which uses diastereoselective reactions to set three stereocenters. The stereochemistry of the anomeric center is controlled by having a 2'-acetoxy directing group, which is subsequently removed by hydrolysis and deoxygenation. This approach requires 4 chromatographic purifications and stoichiometrically uses toxic organotin reagents for late deoxygenation.
[0014] In another approach (see Mark McLaughlin, et al., Enantioselective Synthesis of 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) via Enzymatic Desymmetrization, Organic Letters 2017, 19 (4), pp. 926-929), fully substituted 4'-methanol is generated by enzymatic asymmetric stereoselectivity. The 3'-stereocenter is set by catalytic asymmetric transfer hydrogenation, and the anomeric 1'-key is established with moderate stereoselectivity using substrate control, and the improvement of stereochemical purity is achieved by crystallization of the intermediate. The process requires 15 steps, requires the use of several protecting groups, and produces a glycosyl bond between the nucleobase and the sugar fragment with low stereoselectivity (1.8: 1).
[0015] The 12-step synthesis of EFdA prepared from R-glyceraldehyde acetonide is described in Kageyama, M., et al., Concise Synthesis of the Anti-HIV Nucleoside EFdA, Biosci. Biotechnol. Biochem, 2012, 76, pp. 1219-1225; and Enantioselective Total Synthesis of the Potent Anti-HIV Nucleoside EFdA, Masayuki Kageyama, et al., Organic Letters 2011 13 (19), pp. 5264-5266 [DOI: 10.1021 / ol202116k]. The synthesis uses chiral raw materials to set the 3'-stereocenter with moderate diastereoselectivity. After chromatographic separation of stereoisomers, the new stereocenter is used to guide diastereoselective alkyne addition to set the fully substituted 4'-stereocenter. The anomeric 1'-position is established with little stereocontrol and requires chromatography to separate the anomers. This route requires chromatographic separation of diastereomers at two different stages and starts with expensive chiral starting materials.
[0016] Kohgo, S., et al., Design, Efficient Synthesis, and Anti-HIV Activity of 4'-C-Cyano-and 4'-C-Ethynyl-2'-deoxy Purine Nucleosides, Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, pp. 671–690 [DOI: 10.1081 / NCN-120037508] describes a synthetic approach starting from existing nucleosides and modifying the sugar and nucleobase moieties. This is an 18-step synthesis starting from 2-amino-2'-deoxyadenosine with a low overall yield of 2.5%.
[0017] It is known that enzymes such as purine nucleoside phosphorylase (PNP, EC 2.4.2.1) can form glycosyl bonds in nucleosides and nucleoside analogs with high stereoselectivity and without the use of protecting groups. See, for example, a review: New Trends in Nucleoside Biotechnology, Mikhailopulo, IA, Miroshnikov, AI,. Acta Naturae 2010, 2, pp. 36-58. However, the range of sugar fragments that can undergo reactions catalyzed by PNP is currently limited to the α-1-phosphates of natural ribose and deoxyribose and α-1-phosphates with small H, NH at the C2' and C3' positions. 2 or a small number of analogs with F substituents and C5' OH group replacement. There are no reports of successful glycosylation using sugars with carbon substituents on the ring or any substitution at the C4' position using PNP catalysis.
[0018] PNP-catalyzed glycosylation has been demonstrated to utilize ribose and deoxyribose α-1-phosphate substrates by shifting the phosphate group from the 5'-hydroxyl to the 1'-hydroxyl position using the enzyme phosphopentose mutase (PPM, EC 5.4.2.7) (see Mikhailopulo, IA et al., supra). However, the range of sugars that PPM is able to catalyze this reaction is limited to ribose, arabinose, 2-deoxyribose, and 2,3-dideoxyribose. No examples of successful reactions with sugar phosphates containing any other substituents have been reported.
[0019] It is known that deoxyribose phosphate aldolase (DERA, EC 4.1.2.4) enzymes catalyze the aldol addition of acetaldehyde to other short-chain aldehydes (see review: Stephen M. Dean, et al., Recent Advances in Aldolase-Catalyzed Asymmetric Synthesis, Adv. Synth. Catal. 2007, 349, pp. 1308-1320; DOI: 10.1002 / adsc.200700115). However, there are no reported examples of aldehydes with fully substituted carbon alpha to said aldehydes.
[0020] U.S. Patent 7,229,797 describes the formation of deoxyribonucleosides from natural unsubstituted deoxyribose 1-phosphate by using purine nucleoside phosphorylase (PNP) and additionally using an enzyme such as sucrose phosphorylase to remove inorganic phosphate byproducts and drive equilibrium. It does not disclose the enzyme engineering for producing PNP enzymes that can generate nucleosides from non-natural 4-ethynyl-D-2-deoxyribose 1-phosphate, nor does it disclose that 4-ethynyl-D-2-deoxyribose 1-phosphate can be generated by engineering PPM and DERA enzymes to act on non-natural substrates.
[0021] In view of the difficult and lengthy synthetic options developed to date for the production of 4'-ethynyl nucleoside analogs, it is desirable to develop improved enzymatic syntheses for 4'-ethynyl nucleoside analogs such as EFdA that reduce the number of process steps, minimize the use of protecting groups, improve the stereoselectivity of glycosylation, and avoid the use of toxic substances.
[0022] Surprisingly, it was found that the PPM enzyme has some activity toward a 3-atom ethynyl substituent at the 4' position of ribose, and that the activity of the PPM enzyme can be improved by introducing mutations into the enzyme to successfully develop a reaction for the PPM-catalyzed isomerization of 4-ethynyl-D-2-deoxyribose 5-phosphate (6) to 4-ethynyl-D-2-deoxyribose 1-phosphate (6.5), making possible a more efficient method for producing 4'-ethynyl-2'-deoxynucleosides.
[0023] In addition, it was found that PNPase has some activity towards the 3-atom ethynyl substituent at the 4-position of deoxyribose, and the activity of PNPase can be improved by introducing mutations into the enzyme to successfully develop PNP-catalyzed glycosylation reactions, making possible a more efficient method for producing 4'-ethynyl-2'-deoxynucleosides.
[0024] Even further improvements to the overall synthetic process came from the discovery that DERA enzymes, particularly DERA from Shewanella halifaxensis, are active in aldol reactions with 2-ethynyl-glyceraldehyde 3-phosphate having fully substituted α-carbons. This discovery allowed for the efficient synthesis of 4-ethynyl-D-2-deoxyribose 5-phosphate, a precursor for 4'-ethynyl-2'-deoxynucleoside analogs, including, for example, EFdA. SUMMARY OF THE INVENTION
[0026] The present invention relates to the use of engineered enzymes in a novel enzymatic synthesis of 4'-ethynyl-2'-deoxynucleoside analogs (including EFdA) which eliminates the use of protecting groups on intermediates, improves the stereoselectivity of glycosylation and greatly reduces the number of process steps required to prepare the compounds, as well as other process improvements, compared to existing methods. The invention further relates to novel intermediates which are integral to the enzymatic process.
[0027] The entire process is summarized in Schemes 1 and 2 below; the latter scheme provides an alternative method for preparing compound 5:
[0028] Solution 1
[0029]
[0030] Option 1A
[0031]
[0032] The acid form or salt of the phosphoric acid intermediate can be used in the processes described herein and is not limited to the specific acid or salt form provided in the examples of process steps herein. For all phosphoric acid intermediates described herein, 2X + "" refers to any combination of two protons, a proton and one other monovalent cation, two monovalent cations (the same or different), or a divalent cation. - HO 3 The PO-drawn phosphate intermediates can likewise have any combination of two protons associated with the phosphate group, one proton and one other monovalent cation, two monovalent cations (same or different), or one divalent cation. Examples include, but are not limited to, salts of calcium, magnesium, or zinc; mono- or disodium salts, mono- or dipotassium salts, mono- or dilithium salts; mono- or diammonium salts; mono- or divalent salts with primary, secondary, or tertiary amines.
[0033] As is well understood in the art, intermediate compounds shown or named herein as aldehydes or hydrates in the synthetic steps herein may exist in either form or a mixture of such forms in the reactions described herein. For example, compounds (4) and (5) are depicted as hydrates and aldehydes, respectively, in Scheme 1, but in the reaction steps in which they are each present, they may each exist in the form of a hydrate or aldehyde, or a mixture thereof. In the process steps herein, each such form is encompassed by reference to compound number (4) or (5):
[0034]
[0035] Compound (3) is achiral and may be shown herein as any of the following:
[0036]
[0037] In the reaction steps in which it is present, compound (6) may be present in its ring form or as an open chain aldehyde or hydrate (each as an acid or a salt thereof):
[0038] DETAILED DESCRIPTION OF THE INVENTION
[0040] 4'-Ethynyl-2'-deoxynucleosides and their analogs with anomeric CN bonds have been explored
[0041]
[0042] Activity against HIV, AIDS and related diseases. 4'-ethynyl-2'-deoxynucleosides and their analogs contain 4'-ethynyl-2'-deoxyribose linked to a purine or pyrimidine nucleobase (adenine, guanine, cytosine, thymine or uracil) or a modified purine or pyrimidine nucleobase via an anomeric CN bond.
[0043] It has been discovered that 4'-ethynyl-2'-deoxynucleoside analogs such as EFdA can be synthesized by combining 4-ethynyl-D-2-deoxyribose 5-phosphate (6) with two enzymes, phosphopentosylmutase (PPM) [for example, but not limited to SEQ ID NO.: 8] and purine nucleoside phosphorylase (PNP) [for example, but not limited to SEQ ID NO.: 9, SEQ ID NO.: 15], using a one-pot process as the final step, as shown in Scheme 2.
[0044] Solution 2
[0045]
[0046] Option 2A
[0047]
[0048] As shown in Scheme 2, the final step of the synthesis employs a 2-enzyme reaction with an optional third enzyme to drive the reaction equilibrium toward the desired final product. The final step begins with compound (6) or a salt thereof, wherein (6) is 4-ethynyl-2-deoxyribose 5-phosphate in the cyclic form as shown above or in the form of its open chain aldehyde or hydrate.
[0049] Compound (6) is combined with phosphopentose mutase (PPM), purine nucleoside phosphorylase (PNP), sucrose phosphorylase, sucrose and a nucleobase (e.g., unsubstituted or substituted adenine) in a buffer solution containing a manganese (II) salt and adjusted to a pH range of about 6.5 to 8.0, or more particularly about 7.0 to 7.5 as desired. The molar ratio of sucrose:compound (6) can be, but is not limited to, about 1:1 to 4:1. The components of the one-pot reaction can be combined in any order.
[0050] The reaction is stirred within a temperature range that does not denature the enzyme, for example, about 30 to 45° C., and more particularly about 35 to 45° C. Up to a certain point, cooler temperatures may be effective, but will slow the reaction rate.
[0051] Any buffer having a suitable pH and containing a manganese (II) salt can be used in the reaction. Examples of such buffers include, but are not limited to, triethanolamine; PIPES, such as piperazine-N, N'-bis (2-ethanesulfonic acid); MOPS, such as 3- (N-morpholino) propanesulfonic acid or 3-morpholinopropane-1-sulfonic acid; HEPES, such as 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid or 2- [4- (2-hydroxyethyl) piperazine-1-yl] ethanesulfonic acid; TRIS, such as tris (hydroxymethyl) aminomethane or 2-amino-2- (hydroxymethyl) propane-1,3-diol; and BIS-TRIS methane, such as 2- [bis (2-hydroxyethyl) amino] -2- (hydroxymethyl) propane-1,3-diol. More particularly, the buffer is triethanolamine. The manganese (II) salt in the buffer can be, for example, manganese chloride, manganese chloride hydrate, manganese bromide, manganese iodide, manganese nitrate and / or manganese sulfate. The manganese concentration in the buffer may range from about 0.05 mM to about 10 mM, and particularly about 5 mM.
[0052] The byproduct inorganic phosphate can be consumed by the decomposition of sucrose phosphate into D-fructose and α-D-glucose-1-phosphate catalyzed by sucrose phosphorylase (EC 2.4.1.7) added to the reaction mixture, thereby driving the equilibrium reaction toward high conversion of the final product. However, any other option to remove the phosphate during the reaction can be adopted, such as adding calcium, magnesium or manganese to the reaction to precipitate the phosphate instead of using sucrose phosphorylase and sucrose. The advantage of this efficient and eco-friendly process is that the anomeric bond can be formed between the sugar and the nucleobase with very high stereoselectivity without the use of protecting groups or organic solvents, and can be carried out as a one-pot reaction.
[0053] Once the reaction is complete, the final product can be isolated using standard procedures known to those of ordinary skill in the art, such as, but not limited to, isolation by crystallization of the final product and collection by filtration, or extraction into an appropriate solvent followed by crystallization.
[0054] As shown in Scheme 2A, the final step of the synthesis can alternatively employ a 3-enzyme reaction with an optional fourth enzyme to drive the reaction equilibrium toward the desired final product. The final step begins with compound (5) or a salt thereof, wherein (5) is (R)-2-ethynyl-glyceraldehyde 3-phosphate or a hydrate thereof.
[0055] Compound (5) is combined with deoxyribose phosphate aldolase (DERA), acetaldehyde, phosphopentose mutase (PPM), purine nucleoside phosphorylase (PNP), sucrose phosphorylase, sucrose and a nucleobase or its analog (e.g., unsubstituted or substituted adenine) in a buffer solution containing a manganese (II) salt and adjusted to a pH range of about 4 to 10, or particularly about 6.5 to 8.0, or more particularly about 7.0 to 7.5 as required. The molar ratio of sucrose:compound (5) can be, but is not limited to, about 1:1 to 4:1. The components of the one-pot reaction can be combined in any order.
[0056] The reaction is carried out within a temperature range that does not denature the enzyme, for example about 30 to 45° C., or particularly about 35 to 45° C. Up to a certain point, cooler temperatures may be effective but will slow the reaction rate.
[0057] Acetaldehyde is added in the form of a solution, and more particularly in the form of a 40 wt % solution in isopropanol. Any suitable acetaldehyde solution or pure acetaldehyde may be used in the reaction. Examples of such solutions include, but are not limited to, acetaldehyde solutions in isopropanol, acetaldehyde solutions in ethanol, acetaldehyde solutions in water, acetaldehyde solutions in THF. The molar ratio of aldehyde:compound (5) may be, but is not limited to, about 0.5:1 to 4:1, and more particularly 1.5:1.
[0058] Any buffer having a suitable pH and containing a manganese (II) salt can be used in the reaction. Examples of such buffers include, but are not limited to, triethanolamine; PIPES, such as piperazine-N, N'-bis (2-ethanesulfonic acid); MOPS, such as 3- (N-morpholino) propanesulfonic acid or 3-morpholinopropane-1-sulfonic acid; HEPES, such as 4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid or 2- [4- (2-hydroxyethyl) piperazine-1-yl] ethanesulfonic acid; TRIS, such as tris (hydroxymethyl) aminomethane or 2-amino-2- (hydroxymethyl) propane-1,3-diol; and BIS-TRIS methane, such as 2- [bis (2-hydroxyethyl) amino] -2- (hydroxymethyl) propane-1,3-diol. More particularly, the buffer is triethanolamine. The manganese (II) salt in the buffer can be, for example, manganese chloride, manganese chloride hydrate, manganese bromide, manganese iodide, manganese nitrate and / or manganese sulfate. The manganese concentration in the buffer may range from about 0.05 mM to about 10 mM, and particularly about 5 mM.
[0059] The byproduct inorganic phosphate can be consumed by the decomposition of sucrose phosphate into D-fructose and α-D-glucose-1-phosphate catalyzed by sucrose phosphorylase (EC 2.4.1.7) added to the reaction mixture, thereby driving the equilibrium reaction toward high conversion of the final product. However, any other option to remove the phosphate during the reaction can be adopted, such as adding calcium, magnesium or manganese to the reaction to precipitate the phosphate instead of using sucrose phosphorylase and sucrose. The advantage of this efficient and eco-friendly process is that the anomeric bond can be formed between the sugar and the nucleobase with very high stereoselectivity without the use of protecting groups or organic solvents, and can be carried out as a one-pot reaction.
[0060] Once the reaction is complete, the final product can be isolated using standard procedures known to those of ordinary skill in the art, such as, but not limited to, isolation by crystallization of the final product and collection by filtration, or extraction into an appropriate solvent followed by crystallization.
[0061] As shown in Scheme 3; Scheme 3A and Scheme 3B, several upstream intermediates used in the present process to synthesize the final product 4'-ethynyl-2'-deoxynucleoside and its analogs were also prepared using an enzymatic reaction method.
[0062] Solution 3
[0063]
[0064] Option 3A
[0065]
[0066] Option 3B
[0067]
[0068] Compound 4: Oxidase reaction
[0069] As shown in Scheme 3, (R)-2-ethynyl-glyceraldehyde (4) is prepared by reacting galactose oxidase with 2-ethynyl-propane-1,2,3-triol (3) in a buffer solution adjusted as needed to a pH range of about 3 to 10, or more particularly about 6 to 8. Any buffer having a suitable pH range may be used, such as, but not limited to, sodium phosphate; sodium acetate; PIPES, such as piperazine-N,N'-bis(2-ethanesulfonic acid); MOPS, such as 3-(N-morpholino)propanesulfonic acid or 3-morpholinopropane-1-sulfonic acid; HEPES, such as 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid or 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid; TRIS, such as tris(hydroxymethyl)aminomethane or 2-amino-2- (Hydroxymethyl)propane-1,3-diol; and BIS-TRIS methane, such as 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; borate; CAPS, such as N-cyclohexyl-3-aminopropanesulfonic acid; MES, such as 2-(N-morpholino)ethanesulfonic acid; CHES, such as N-cyclohexyl-2-aminoethanesulfonic acid; glycine; or Bicine (N,N-bis(2-hydroxyethyl)glycine); among which sodium phosphate is preferred.
[0070] Both copper and peroxidase are used in the reaction to activate galactose oxidase (GOase). This can be achieved by adding CuSO 4 、Cu(OAc) 2 , CuCl 2 Or other salts of Cu(II) or Cu(I) supply copper to the reaction mixture. The peroxidase can be horseradish peroxidase, or peroxidase derived from other organisms, or it can be replaced by an oxidant, such as ferrocyanide, iridate, manganese(III) salts, persulfate and other one or two electron oxidants, or inorganic or organic oxidants. Preferably, the peroxidase is horseradish peroxidase. Catalase is also added to help prevent GOase from inactivation. Catalase can be from mammalian sources (cattle) or from bacterial or fungal sources, such as Corynebacterium, Aspergillus or other organisms known in the art for this purpose.
[0071] The reaction is carried out in the presence of oxygen. A convenient method is to bubble the reaction with air. Alternatively, other systems for generating oxygen may be employed, such as hydrogen peroxide / catalase, superoxide or using other methods known in the art for this purpose.
[0072] The reaction may be carried out at a substrate concentration of about 10 to 180 g / L, and particularly 20 to 50 g / L. The reaction may be run at a temperature of about 0 to 40°C, and particularly about 10 to 30°C.
[0073] Compound 8: Aminal formation
[0074] As illustrated in Scheme 3A, (R)-2-ethynyl-glyceraldehyde (4) can be isolated as the aminal form of (R)-2-ethynyl-glyceraldehyde (4) (e.g., compound 8) by reacting it with any amine, diamine, or amino alcohol that forms a stable N,N-acetal or N,O-acetal (e.g., but not limited to, N,N'-dibenzylethane-1,2-diamine, N,N'-dimethylethane-1,2-diamine, N,N'-diphenylethane-1,2-diamine, and N-benzylethanolamine; wherein N,N'-dibenzylethane-1,2-diamine is preferred). The reaction is carried out in an organic solvent at a temperature of about 50° C. or less, preferably 20 to 30° C., to avoid decomposition of the aminal. Any solvent immiscible with water can be used, such as but not limited to MTBE, 2-MeTHF, CPME, ether, diisopropyl ether, ethyl acetate, isopropyl acetate, toluene, DCM or a mixture thereof, wherein MTBE is preferred. The reaction can be carried out at a substrate concentration of about 10 to 100 g / L, and particularly 20 to 50 g / L.
[0075] Optionally, the aminal can be further purified by crystallization from an organic solvent (such as but not limited to MTBE, 2-MeTHF, CPME, ether, diisopropyl ether, ethyl acetate, isopropyl acetate, toluene, DCM or a mixture thereof, wherein MTBE is preferred). The crystallization is carried out at or below 50° C., such as at about 40° C., to avoid decomposition of the aminal.
[0076] The reaction is carried out in the absence of oxygen. A convenient method is to use N 2 Bubble the reaction. Alternatively, other systems to exclude oxygen may be employed, such as argon, helium, or using other methods known in the art for this purpose.
[0077] Compound 4: Regeneration of aldehyde 4 from aminal 8
[0078] (R)-2-ethynyl-glyceraldehyde (4) can be regenerated from its corresponding aminal by reacting it with an organic or inorganic acid in the presence of an organic solvent immiscible with water at a temperature of 50°C or below, such as about 0 to 15°C, to avoid decomposition of the aminal. Any organic or inorganic acid can be used, such as but not limited to p-toluenesulfonic acid, methanesulfonic acid, camphorsulfonic acid, acetic acid, hydrochloric acid, phosphoric acid, sulfuric acid. Due to the low solubility of N,N'-dibenzylethane-1,2-diamine bis-p-toluenesulfonate in water, p-toluenesulfonic acid is preferred in the reaction with aminal 8. Any solvent immiscible with water can be used, such as but not limited to MTBE, 2-MeTHF, CPME, ether, diisopropyl ether, ethyl acetate, isopropyl acetate, toluene, DCM or mixtures thereof; MTBE and 2-MeTHF are preferred. The reaction can be carried out at a substrate concentration of about 5 to 100 g / L, and particularly 20 to 50 g / L.
[0079] Optionally, the aldehyde 4 solution can be further treated with a resin to remove excess organic or inorganic acid. Basic resins such as DOWEX TM MARATHON TM A resin (hydroxide type) and 15 resin (hydrogen type) or its mixture for resin treatment, preferably DOWEX TM MARATHON TM A resin (hydroxide type) and 15 resin mixture.
[0080] Optionally, the aldehyde 4 solution can be further evaporated under vacuum or under a gas purge to remove excess organic solvent.
[0081] Compound 5: Kinase reaction
[0082]
[0083] As shown in Scheme 3 and Scheme 3A, (R)-2-ethynyl-glyceraldehyde 3-phosphate hydrate (5) is prepared by reacting pantothenate kinase (PanK) wild type or a variant thereof from Escherichia coli with compound (4) in a buffer solution adjusted to a pH range of about 4 to 10, or particularly about 6.5 to 8.5, or more particularly 5.5 to 8.5 as required. Any buffer with a suitable pH range may be used, such as, but not limited to, sodium phosphate, PIPES, such as piperazine-N,N'-bis(2-ethanesulfonic acid); BIS-TRIS methane, such as 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; borate; HEPES, such as 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid or 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid; triethanolamine and TRIS, such as TRIS, such as tris(hydroxymethyl)aminomethane or 2-amino-2-(hydroxymethyl)propane-1,3-diol; wherein sodium phosphate is preferred. The reaction may be carried out in the presence of any suitable divalent metal salt, such as, but not limited to, magnesium salts, such as magnesium chloride, and salts of cobalt, manganese, zinc or calcium.
[0084] The reaction utilizes 5'-adenosine diphosphate (ADP) as a phosphate source, which needs to be regenerated into 5'-triphosphate (ATP). ATP can be generated in situ and subsequently regenerated from ADP, 5'-adenosine monophosphate (AMP) or adenosine by any method known in the art. For example, the combination of acetyl phosphate and acetate kinase can be used to regenerate ADP into ATP. For example, in the presence of pyruvate, phosphoric acid and oxygen, the combination of pyruvate oxidase and catalase generates acetyl phosphate, and therefore in the presence of acetate kinase, can be used to regenerate ADP into ATP.
[0085] The reaction may be carried out at a substrate concentration of about 10 to 100 g / L, and particularly about 20 to 40 g / L. The reaction may be run at a temperature of about 0 to 40°C, and particularly about 10 to 25°C.
[0086] The reaction can also be carried out with pantothenate kinase (PanK) fixed on the resin or with both PanK and acetate kinase fixed on the resin. Any suitable enzyme immobilization method known in the art can be used, such as but not limited to immobilized metal ion affinity chromatography (IMAC) resin, or affinity resin immobilization using other biotags, covalent immobilization, immobilization on ionic resin, immobilization by adsorption, encapsulation and / or cross-linking enzyme. For example, metal ion affinity chromatography (IMAC) resin can be used, or any suitable combination of IMAC resin and divalent cation can be used, wherein the cation can be, for example, but not limited to nickel, cobalt, copper, zinc, iron and / or aluminum. In particular, IMAC resin with nickel can be used. Preferably, acetate kinase and pantothenate kinase (PanK) are both fixed on the resin.
[0087] Compound 9: Kinase reaction
[0088]
[0089] As shown in Scheme 3B, (S)-2-ethynyl-propane-1,2,3-triol 1-phosphate (9) is prepared by reacting pantothenate kinase (PanK) wild type or a variant thereof from Escherichia coli with compound (3) in a buffer solution adjusted to a pH range of about 4 to 10, or particularly about 6.5 to 8.5, or more particularly 5.5 to 8.5 as required. Any buffer with a suitable pH range may be used, such as, but not limited to, sodium phosphate; PIPES, such as piperazine-N,N'-bis(2-ethanesulfonic acid); BIS-TRIS methane, such as 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; borate; HEPES, such as 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid or 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid; triethanolamine and TRIS, such as tris(hydroxymethyl)aminomethane or 2-amino-2-(hydroxymethyl)propane-1,3-diol, with sodium phosphate being preferred. The reaction may be carried out in the presence of any suitable divalent metal salt, such as, but not limited to, magnesium salts, such as magnesium chloride, and salts of cobalt, manganese, zinc or calcium.
[0090] The reaction utilizes 5'-adenosine diphosphate (ADP) as a phosphate source, which needs to be regenerated into 5'-triphosphate (ATP). ATP can be generated in situ and subsequently regenerated from ADP, 5'-adenosine monophosphate (AMP) or adenosine by any method known in the art. For example, a combination of acetyl phosphate and acetate kinase can be used to regenerate ADP into ATP. Alternatively, (a) a combination of pyruvate oxidase, catalase and acetate kinase in the presence of pyruvate, phosphoric acid and oxygen can be used to regenerate ADP into ATP, or (b) a combination of pyruvate oxidase, catalase and acetate kinase in the presence of pyruvate, phosphoric acid and oxygen can be used to regenerate ATP from ADP in combination with acetyl phosphate and acetate kinase.
[0091] The reaction may be carried out at a substrate concentration of about 10 to 100 g / L, and particularly about 20 to 40 g / L. The reaction may be run at a temperature of about 0 to 40°C, and particularly about 10 to 25°C.
[0092] The reaction can also be carried out with pantothenate kinase (PanK) fixed on the resin or with both PanK and acetate kinase fixed on the resin. Any suitable enzyme immobilization method known in the art can be used, such as but not limited to immobilized metal ion affinity chromatography (IMAC) resin, or affinity resin immobilization using other biotags, covalent immobilization, immobilization on ionic resin, immobilization by adsorption, encapsulation and / or cross-linking enzyme. For example, metal ion affinity chromatography (IMAC) resin can be used, or any suitable combination of IMAC resin and divalent cation can be used, wherein the cation can be, for example, but not limited to nickel, cobalt, copper, zinc, iron and / or aluminum. In particular, IMAC resin with nickel can be used. Preferably, acetate kinase and pantothenate kinase (PanK) are both fixed on the resin.
[0093] Compound 5: Oxidase reaction
[0094]
[0095] As shown in Scheme 3B, (R)-2-ethynyl-glyceraldehyde hydrate 3-phosphate (5) is prepared by reacting galactose oxidase with (S)-2-ethynyl-propane-1,2,3-triol 1-phosphate (9) in a buffer solution adjusted as needed to a pH range of about 3 to 10, or more particularly about 6 to 8. Any buffer having a suitable pH range may be used, such as, but not limited to, sodium phosphate; sodium acetate; PIPES, such as piperazine-N,N'-bis(2-ethanesulfonic acid); MOPS, such as 3-(N-morpholino)propanesulfonic acid or 3-morpholinopropane-1-sulfonic acid; HEPES, such as 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid or 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid; TRIS, such as tris(hydroxymethyl)aminomethane or 2-amino-2- (Hydroxymethyl)propane-1,3-diol; and BIS-TRIS methane, such as 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; borate; CAPS, such as N-cyclohexyl-3-aminopropanesulfonic acid; MES, such as 2-(N-morpholino)ethanesulfonic acid; CHES, such as N-cyclohexyl-2-aminoethanesulfonic acid; glycine; or Bicine (N,N-bis(2-hydroxyethyl)glycine); among which sodium phosphate is preferred.
[0096] Both copper and peroxidase are used in the reaction to activate galactose oxidase (GOase). This can be achieved by adding CuSO 4 、Cu(OAc) 2 , CuCl 2Or other salts of Cu(II) or Cu(I) supply copper to the reaction mixture. The peroxidase can be horseradish peroxidase, or peroxidase derived from other organisms, or it can be replaced by an oxidant, such as ferrocyanide, iridate, manganese(III) salts, persulfate and other one or two electron oxidants, or inorganic or organic oxidants. Preferably, the peroxidase is horseradish peroxidase. Catalase is also added to help prevent GOase from inactivation. Catalase can be from mammalian sources (cattle) or from bacterial or fungal sources, such as Corynebacterium, Aspergillus or other organisms known in the art for this purpose.
[0097] The reaction is carried out in the presence of oxygen. A convenient method is to bubble the reaction with air. Alternatively, other systems for generating oxygen may be employed, such as hydrogen peroxide / catalase, superoxide or using other methods known in the art for this purpose.
[0098] The reaction may be carried out at a substrate concentration of about 10 to 180 g / L, and particularly 20 to 50 g / L. The reaction may be run at a temperature of about 0 to 40°C, and particularly about 10 to 30°C.
[0099] Compound 6: Deoxyribose phosphate aldolase (DERA) reaction
[0100] An important advantage of this new route for the production of compound (6) compared to currently known processes is that it produces the sugar backbone in the correct oxidation state without the use of protecting groups.
[0101] 4-Ethynyl-D-2-deoxyribose 5-phosphate (6) is prepared by reacting deoxyribose phosphate aldolase (DERA) with (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) (as an acid or a salt thereof) and acetaldehyde in an aqueous solution adjusted as needed to a pH range of about 5 to 9, or more particularly about 6 to 8. Examples of salts of (5) include, but are not limited to, calcium, magnesium, zinc, mono- or disodium, mono- or dipotassium, or mono- or dilithium salts; mono- or diammonium or salts; or mono- or divalent salts of primary, secondary, or tertiary amines. The reaction can be carried out in an open container or preferably in a sealed container to prevent evaporation of acetaldehyde.
[0102] The reaction can be carried out at a substrate concentration of about 10 to 100 g / L, particularly about 30 to 60 g / L. It can be run at a temperature of about 0 to 40°C, and particularly about 25 to 35°C.
[0103] The reaction can be run without any buffer. Alternatively, a buffer such as, but not limited to, triethanolamine, phosphate, MOPS, such as 3-(N-morpholino)propanesulfonic acid or 3-morpholinopropane-1-sulfonic acid, HEPES, such as 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid or 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid, BIS-TRIS methane, such as 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol, borate, PIPES, such as piperazine-N,N'-bis(2-ethanesulfonic acid), MES, such as 2-(N-morpholino)ethanesulfonic acid, and borate, or other buffers having a suitable pH range without any primary amine groups, can be used.
[0104] Each step and method of the process described herein including the use of one or more enzymes is carried out at a temperature that does not denature the one or more enzymes. Each step and method of the process described herein including the use of one or more enzymes can be carried out at a pH range of about 3 to 10 or about 4 to 10.
[0105] "Nucleobases" (or "nitrogenous bases" or "bases") are pyrimidine or purine heterocycles of nucleic acids, such as DNA and RNA. As used herein, nucleobases include adenine, guanine, cytosine, thymine, or uracil, as well as nucleobases with non-natural modifications, for example, wherein the base has one or more non-natural substituents, or modifications that affect heteroatoms in the base, excluding any changes in the anomeric CN bond.
[0106] 4'-ethynyl-2'-deoxynucleosides contain nucleobases. As used herein, analogs of 4'-ethynyl-2'-deoxynucleosides refer to non-natural modifications of nucleoside bases, such as where the base has one or more non-natural substituents, or modifications that affect heteroatoms in the base, excluding any changes in the anomeric CN bond.
[0107] As used herein, a "phosphopentose mutase" ("PPM") enzyme (eg, EC 5.4.2.7) is an enzyme that catalyzes the reversible isomerization of ribose 1-phosphate to ribose 5-phosphate and related compounds such as deoxyribose phosphate and analogs of ribose phosphate and deoxyribose phosphate.
[0108] As used herein, "purine nucleoside phosphorylase" ("PNP") enzymes (EC 2.4.2.2) are enzymes that catalyze the reversible phosphorolysis of purine ribonucleosides and related compounds (e.g., deoxyribonucleosides and analogs of ribonucleosides and deoxyribonucleosides) to free purine bases and ribose-1-phosphate (and their analogs).
[0109] As used herein, a "sucrose phosphorylase" ("SP") enzyme (EC 2.4.1.7) is an enzyme that catalyzes the reversible phosphorolysis of sucrose into D-fructose base and glucose-1-phosphate (and its analogs). The combination of sucrose phosphorylase (SP) and sucrose is employed in conjunction with purine nucleoside phosphorylase (PNP) and phosphomutase (PPM) to remove free phosphate ions from the reaction, wherein the combination of enzymes catalyzes the formation of the nucleoside MK-8591 (EFdA), while in some embodiments, it may be replaced by other methods known in the art.
[0110] As used herein, "deoxyribose phosphate aldolase" ("DERA") (e.g., EC 4.1.2.4) refers to an enzyme in the cleavage enzyme family that reversibly cleaves or generates carbon-carbon bonds. Deoxyribose phosphate aldolase used herein includes naturally occurring (wild-type) deoxyribose phosphate aldolase and non-naturally occurring engineered polypeptides generated by human manipulation. Wild-type deoxyribose phosphate aldolase catalyzes the reversible reaction of 2-deoxy-D-ribose 5-phosphate to D-glyceraldehyde 3-phosphate and acetaldehyde.
[0111] As used herein, "pantothenate kinase" ("PanK") refers to an enzyme (EC 2.7.1.33) that essentially phosphorylates pantothenate to form 4'-phosphopantothenate. Variant enzymes derived from such PanK enzymes may show improved activity and stereoselectivity for the 3'OH-group of D-ethynylglyceraldehyde, regardless of whether such variants retain their native function for pantothenate.
[0112] As used herein, "galactose oxidase" ("GOase"; EC 1.1.3.9) enzymes are copper-dependent enzymes that catalyze the oxidation of primary alcohols to the corresponding aldehydes in the presence of dimolecular oxygen. They act in a regio- and enantio-specific manner, enabling synthetic methods that require little functional group protection and produce the desired stereoisomers. The mode of oxidation is mild and controlled so that the activity does not result in over-oxidation of the alcohol to its corresponding carboxylic acid.
[0113] As used herein, "horseradish peroxidase" (HRP, EC 1.11.1.7) enzymes are iron-dependent enzymes that activate and maintain GOase catalytic activity by oxidizing the inactive redox state of the active site that occurs during the normal GOase catalytic cycle. Type I HRP is employed catalytically in the embodiments included herein, however, it is not intended to be exclusive in this role, as there are other electron transfer enzymes belonging to this class and other enzyme classes, as well as chemical reagents that can achieve this role.
[0114] As used herein, "catalase" refers to a heme-dependent enzyme (EC 1.11.1.6) that acts on hydrogen peroxide, which is a byproduct of the galactose oxidase or pyruvate oxidase reactions, which can inactivate the enzyme above a certain level of hydrogen peroxide. Catalase is used as a catalytically sustaining enzyme in the examples herein to convert hydrogen peroxide into water and oxygen, while in some embodiments, it can be replaced by other methods, such as electrochemical decomposition of hydrogen peroxide. Heme-dependent catalase is used in a catalytic manner in the examples included herein, however, it is not meant to be exclusive in this role, as there are other enzymes belonging to this class that can achieve this role.
[0115] As used herein, "acetate kinase" ("AcK") refers to an enzyme (EC 2.7.2.1) that catalyzes the formation of acetyl phosphate from acetate and adenosine triphosphate (ATP). It can also catalyze the reverse reaction, in which 5'-adenosine diphosphate (ADP) is phosphorylated to 5'-adenosine triphosphate (ATP) in the presence of acetyl phosphate. In the examples herein, acetate kinase is used to recycle the ATP required for pantothenate kinase (PanK), while in some embodiments, other methods known in the art can be used instead of the recycling combination of acetyl phosphate-acetate kinase.
[0116] As used herein, "pyruvate oxidase" ("PO") refers to an enzyme that is dependent on flavin adenine dinucleotide (FAD) and thiamine diphosphate (EC 1.2.3.3). Pyruvate oxidase is an enzyme belonging to the oxidoreductase family, particularly those enzymes that act on an aldehyde or oxo group of a donor with oxygen as an acceptor, and it catalyzes the chemical reaction between pyruvate, phosphate ions, and dimolecular oxygen to form acetyl phosphate, carbon dioxide, and hydrogen peroxide. In the examples herein, pyruvate oxidase (PO) is used as a catalytic ATP regeneration combination in combination with acetate kinase (AcK) and catalase, wherein the combination of enzymes catalyzes the formation of ATP from ADP in the presence of oxygen, pyruvate, and phosphate ions, and in some embodiments, it can be replaced by other methods known in the art.
[0117] As used herein, "wild-type" and "naturally occurring" enzymes refer to the form found in nature. For example, a wild-type polypeptide sequence is a sequence present in an organism that can be isolated from a source in nature and has not been intentionally modified by human manipulation.
[0118] As used herein, "engineered," "variant," "mutant," and "non-naturally occurring" when used in reference to enzymes including polypeptides, refer to materials, or materials corresponding to the natural or native form of the material, that have been modified in a manner that does not otherwise occur in nature. In some embodiments, the polypeptide is identical to a naturally occurring polypeptide, but is produced or derived from synthetic materials and / or by manipulation using recombinant techniques.
[0119] "Percentage of sequence identity", "percent identity" and "percent identical" with respect to enzymes are used herein to refer to comparisons between polynucleotide sequences or between polypeptide sequences, and are determined by comparing two optimally aligned sequences over a comparison window, wherein for optimal alignment of the two sequences, the portion of the polynucleotide or polypeptide sequence within the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence. The percentage is calculated by determining the number of positions where the same nucleic acid base or amino acid residue appears in the two sequences or the number of positions where the nucleic acid base or amino acid residue is aligned with the gap to produce the number of matching positions, dividing the number of matching positions by the total number of positions in the comparison window and multiplying the result by 100 to produce the percentage of sequence identity. Optimal alignment and determination of percentage sequence identity are performed using BLAST and BLAST 2.0 algorithms (see, e.g., Altschul et al., 1990, J. Mol. Biol. 215: 403-410 and Altschul et al., 1977, Nucleic Acids Res. 3389-3402). Software for performing BLAST analyses is publicly available from the National Center for Biotechnology Information website.
[0120] Briefly, BLAST analysis involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that, when aligned with a word of the same length in a database sequence, either match or satisfy some positive-valued threshold score T. T is called the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word matches serve as seeds for initiating searches to find longer HSPs containing them. Word matches are then extended in both directions along each sequence as far as the cumulative alignment score can be increased. For nucleotide sequences, cumulative scores are calculated using the parameters M (reward score for matching residue pairs; always >0) and N (penalty score for mismatched residues; always <0). For amino acid sequences, a scoring matrix is used to calculate cumulative scores. Extension of word matches in each direction ceases when: the cumulative alignment score drops from its maximum achieved value by the amount X; the cumulative score becomes zero or below zero due to the accumulation of one or more negative scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expectation value € of 10, M=5, N=-4, and a comparison of both chains as defaults. For amino acid sequences, the BLASTP program uses a word length (W) of 3, an expectation value € (E) of 10, and the BLOSUM62 scoring matrix as defaults (see Henikoff and Henikoff, 1989, Proc Natl Acad Sci USA 89:10915).
[0121] A number of other algorithms are available that function similarly to BLAST in providing percent identity between two sequences. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith and Waterman, 1981, Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the GCG Wisconsin Software Package), or by visual inspection (see generally, Current Protocols in Molecular Biology, FM Ausubel et al., eds., Current Protocols, a joint venture of Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)). Additionally, sequence alignments and determination of percent sequence identity can be performed using the BESTFIT or GAP programs in the GCG Wisconsin Software package (Accelerys, Madison WI) using the default parameters provided.
[0122] "Substantial identity" refers to a polynucleotide or polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity when compared to a reference sequence over a comparison window of at least 20 residue positions, usually over a window of at least 30-50 residues, wherein the percentage of sequence identity is calculated by comparing the reference sequence with a sequence comprising a total of 20% or less deletion or addition of the reference sequence over the comparison window. In a specific embodiment applied to polypeptides, the term "substantial identity" means that when optimally aligned, for example, by the program GAP or BESTFIT using the default gap weight, two polypeptide sequences have at least 80% sequence identity, preferably at least 89% sequence identity, more preferably at least 95% sequence identity or more (e.g., 99% sequence identity). Preferably, non-identical residue positions differ by conservative amino acid substitutions.
[0123] "Stereoselectivity" refers to the preferred formation of one stereoisomer over another in a chemical or enzymatic reaction. Stereoselectivity can be partial, where the formation of one stereoisomer is superior to another, or stereoselectivity can be complete, where only one stereoisomer is formed. When stereoisomers are enantiomers, stereoselectivity is called enantioselectivity, i.e. the fraction (usually reported as a percentage) of one enantiomer in the sum of the two. Alternatively, it is usually reported in the art as the enantiomeric excess (ee) (usually a percentage) calculated therefrom according to the formula [major enantiomer-minor enantiomer] / [major enantiomer+minor enantiomer]. In the case where the stereoisomer is a diastereoisomer, stereoselectivity is called diastereoselectivity, i.e. the fraction (usually reported as a percentage) of one diastereoisomer in a mixture of two diastereomers, usually reported as diastereomeric excess (de) instead. Enantiomeric excess and diastereomeric excess are types of stereoisomer excess.
[0124] The phrase "suitable reaction conditions" refers to those conditions (e.g., enzyme loading range, substrate loading, temperature, pH, buffer, cosolvent, etc.) in the enzymatic conversion reaction solution under which each polypeptide used in the present invention is able to convert a substrate into a desired product compound. Some exemplary suitable reaction conditions are provided herein.
[0125] As used herein, in the context of an enzymatic conversion reaction process, "substrate" refers to a compound or molecule that is acted upon by the engineered enzyme used herein.
[0126] As used herein, in the context of an enzymatic conversion process, "product" refers to a compound or molecule resulting from the action of an enzymatic polypeptide on a substrate.
[0127] As used herein, the yield of a product of a reaction (e.g., a 4'-ethynyl-2'-deoxyribose phosphate analog or a 4'-ethynyl-2'-deoxynucleoside analog) is "increased" when the presence of a particular component (e.g., an enzyme) during the reaction results in the production of more product compared to a reaction performed under the same conditions with the same substrate but without the target component.
[0128] As used herein, "equilibrium" or "equilibrium" as used herein refers to the process leading to a steady-state concentration of a chemical species in a chemical or enzymatic reaction (e.g., the interconversion of two species A and B), including the interconversion of stereoisomers, as determined by the forward rate constant and the reverse rate constant of the chemical or enzymatic reaction.
[0129] "Enantiomeric excess" (ee) is a measure of purity for chiral substances. It reflects the extent to which a sample contains more of one enantiomer than the other. For example, a racemic mixture has 0% ee, while a single, completely pure enantiomer has 100% ee; and a sample containing 70% of one enantiomer and 30% of the other has an ee of 40% (70% - 30%). When only two diastereomers are present in the mixture, the diastereomeric excess (de) is calculated in the same way as ee.
[0130] "Protein," "enzyme," "polypeptide," and "peptide" are used interchangeably herein to refer to a polymer of at least two amino acids covalently linked by an amide bond, regardless of length or post-translational modifications (e.g., glycosylation, phosphorylation, lipidation, myristoylation, ubiquitination, etc.). Included in this definition are D- and L-amino acids, as well as mixtures of D- and L-amino acids.
[0131] As used herein, the term "about" refers to an acceptable error for a particular value. In some cases, "about" means within 0.05%, 0.5%, 1.0%, or 2.0% of the lower and upper ends of a given range of values. With respect to pH, "about" means plus or minus 0.5.
[0132] As used herein, "substantially pure" polypeptide or "purified" protein refers to a composition in which the polypeptide substance is the main substance present (i.e., in moles or weight, it is more abundant than any other individual macromolecular substance in the composition), and when the target substance contains at least about 50% of the macromolecular substance present in moles or % weight, the composition is generally a substantially purified composition. However, in some embodiments, the composition comprising the polypeptide comprises a polypeptide having a purity of less than 50% (e.g., about 10%, about 20%, about 30%, about 40% or about 50%). Typically, a substantially pure polypeptide composition comprises all macromolecular substances present in the composition in moles or % weight of about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, and about 98% or more. In some embodiments, the polypeptide is purified to substantially homogeneity (i.e., contaminating substances cannot be detected in the composition by conventional detection methods), wherein the composition is substantially composed of a single macromolecular substance. Solvent substances, small molecules (<500 Daltons) and elemental ion substances are not considered macromolecular substances. In some embodiments, an isolated polypeptide is a substantially pure polypeptide composition.
[0133] As used herein, an "improved property" of an enzyme refers to at least one improved property of an enzyme. In some embodiments, the present invention employs an engineered PPM, PNP, DERA, PanK, AcK, SP and / or GOase polypeptide that exhibits improvement in any enzyme property compared to a reference PPM, PNP, DERA, PanK, AcK, SP or GOase polypeptide, and / or to a wild-type PPM, PNP, DERA, PanK, AcK, SP or GOase polypeptide, and / or to another engineered PPM, PNP, DERA, PanK, AcK, SP or GOase polypeptide, respectively. Thus, the level of "improvement" can be determined and compared between various polypeptides, including wild-type and engineered polypeptides. Improved properties include, but are not limited to, properties such as increased protein expression, increased production of desired product, increased substrate specificity or affinity (i.e., increased activity toward substrate), increased thermal activity, increased thermal stability, increased pH activity, increased stability, increased enzymatic activity, increased specific activity, increased resistance to substrate or end-product inhibition, increased chemical stability, improved chemoselectivity, improved solvent stability, increased tolerance to acidic pH, increased tolerance to proteolytic activity (i.e., reduced susceptibility to proteolysis), reduced aggregation, increased solubility, and altered temperature profile. In additional embodiments, the term is used to refer to at least one improved property of a PPM, PNP, DERA, PanK, AcK, SP, and / or GOase enzyme. In some embodiments, the invention employs an engineered PPM, PNP, DERA, PanK, AcK, SP and / or GOase polypeptide that exhibits an improvement in any enzyme property compared to a reference PPM, PNP, DERA, PanK, AcK, SP and / or GOase polypeptide, respectively; and / or to a wild-type polypeptide, and / or to another engineered PPM, PNP, DERA, PanK, AcK, SP and / or GOase polypeptide, respectively. Thus, the level of "improvement" can be determined and compared between various polypeptides, including wild-type as well as engineered polypeptides.
[0134] As used herein, "conversion" ("conv" or "conv.") refers to the enzymatic conversion (or bioconversion) of a substrate to the corresponding product. The "percentage" of conversion refers to the percentage of substrate converted to product under specified conditions within a certain period of time. Thus, the "enzymatic activity" or "activity" of a polypeptide can be expressed as the percentage of conversion of a substrate to a product within a specific period of time.
[0135] As used herein, "stereoselectivity" refers to the preferred formation of one stereoisomer over another in a chemical or enzymatic reaction. Stereoselectivity can be partial, where the formation of one stereoisomer is superior to another, or stereoselectivity can be complete, where only one stereoisomer is formed. When stereoisomers are enantiomers, stereoselectivity is called enantioselectivity, i.e., the fraction (usually reported as a percentage) of one enantiomer in the sum of the two. Alternatively, it is usually reported in the art as the enantiomeric excess ("ee") (usually a percentage) calculated therefrom according to the formula [major enantiomer-minor enantiomer] / [major enantiomer+minor enantiomer]. In the case where the stereoisomer is a diastereoisomer, stereoselectivity is called diastereoselectivity, i.e., the fraction (usually reported as a percentage) of one diastereoisomer in a mixture of two diastereomers, usually reported as diastereomeric excess ("de") instead. Enantiomeric excess and diastereomeric excess are types of stereoisomer excess.
[0136] The process of the present invention includes the use of engineered PPM, PNP, DERA, PanK, AcK, SP and GOase polypeptides, particularly polypeptides having SEQ ID NO.s 1 to 21, as well as said sequences comprising one or more conservative amino acid substitutions, which can be referred to as conservatively modified variants of each of SEQ ID NO.s 1 to 21.
[0137] As used herein, "conservative" amino acid substitutions refer to amino acids in a protein being replaced by other amino acids having similar characteristics (e.g., acidity, alkalinity, positive or negative charge, polarity or non-polarity, side chain size, hydrophobicity / hydrophilicity, backbone conformation and rigidity, etc.), so that changes can be made frequently without changing the biological activity of the protein. This includes one or more replacements of amino acids in a polypeptide with different amino acids within the same or similarly defined amino acid classes. Those skilled in the art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide will not substantially change biological activity (see, e.g., Watson et al. (1987) Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224 (4th Ed.)). In addition, substitutions of amino acids that are similar in structure or function are less likely to destroy biological activity. By way of example and not limitation, in some embodiments, an amino acid with an aliphatic side chain is replaced by another aliphatic amino acid (e.g., alanine, valine, leucine, and isoleucine); an amino acid with a hydroxyl side chain is replaced by another amino acid with a hydroxyl side chain (e.g., serine and threonine); an amino acid with an aromatic side chain is replaced by another amino acid with an aromatic side chain (e.g., phenylalanine, tyrosine, tryptophan, and histidine); an amino acid with a basic side chain is replaced by another amino acid with a basic side chain (e.g., lysine and arginine); an amino acid with an acidic side chain is replaced by another amino acid with an acidic side chain (e.g., aspartic acid or glutamic acid); and / or a hydrophobic or hydrophilic amino acid is replaced by another hydrophobic or hydrophilic amino acid, respectively. Table 1 lists other exemplary conservative amino acid substitutions.
[0138] Table 1. Exemplary conservative amino acid substitutions
[0139]
[0140]
[0141] The term "amino acid substitution group" or "substitution group" refers to a group of amino acid substitutions in a polypeptide sequence compared to a reference sequence. A substitution group can have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more amino acid substitutions.
[0142] A "functional fragment" refers to a polypeptide having an amino-terminal and / or carboxyl-terminal deletion and / or an internal deletion, but wherein the remaining amino acid sequence is identical to the corresponding positions in the sequence to which it is compared (e.g., the full-length engineered PPM, PNP, DERA, PanK, AcK, SP or GOase enzyme used in the present invention) and substantially retains all the activities of the full-length polypeptide.
[0143] As used herein, "deletion" refers to a modification of a polypeptide by removing one or more amino acids from a reference polypeptide. Deletion may include removal of 1 or more amino acids, 2 or more amino acids, 5 or more amino acids, 10 or more amino acids, 15 or more amino acids, or 20 or more amino acids, up to 10% of the total number of amino acids constituting the reference enzyme, or up to 20% of the total number of amino acids constituting the reference enzyme, while retaining enzymatic activity and / or retaining the improved properties of the engineered PPM, PNP, DERA, PanK, AcK, SP or GOase enzyme. Deletion may be directed to the internal portion and / or terminal portion of the polypeptide. In various embodiments, deletion may comprise a continuous segment or may be discontinuous. Deletion is usually represented by "-" in the amino acid sequence.
[0144] As used herein, "insertion" refers to a modification of a polypeptide by adding one or more amino acids from a reference polypeptide. The insertion may be in an internal portion of a polypeptide, or at the carboxyl or amino terminus. Insertions as used herein include fusion proteins as known in the art. Insertions may be contiguous stretches of amino acids or separated by one or more amino acids in a naturally occurring polypeptide.
[0145] Other acronyms and abbreviations used in this article are as follows:
[0146] LC-MS Liquid chromatography-mass spectrometry g / L g / L THF Tetrahydrofuran mL ml NMR Nuclear magnetic resonance spectroscopy mmol mmol RT or rt Room temperature (ambient, about 25°C) mg mg sccm Standard cubic centimeters per minute kg kilogram rpm Revolutions / minute N Equivalent concentration M Mole / mol concentration conv Conversion rate mM Millimolar concentration NMR Nuclear Magnetic Resonance μL microliter aq Watery DMSO Dimethyl sulfoxide hr,h Hour TxD p-Toluenesulfonic acid HPLC High performance liquid chromatography Bn Benzyl DCM Dichloromethane CPME Cyclopentyl methyl ether 2-MeTHF 2-Methyltetrahydrofuran MTBE Methyl tert-butyl ether ESI Electrospray ionization HR-MS High-resolution mass spectrometry .
[0147] Experimental Procedure
[0148] Preparation of 2-ethynyl-2-hydroxypropane diacetate (2)
[0149] Method A:
[0150]
[0151] To a -35°C solution of diacetoxyacetone (1) (159 g, 914.0 mmol) in THF (1000 mL) was added 1600 mL of a 0.5 M solution of ethynylmagnesium chloride in THF, keeping the temperature below -20°C. After the reaction reached completion, acetic acid (78 mL) in 400 mL of methyl tert-butyl ether (MTBE) was added dropwise, keeping the temperature below -20°C. MTBE (800 mL) was then added, and the mixture was warmed to room temperature. Saturated aqueous NaCl solution (1000 mL) was added, followed by saturated NH 4 Cl aqueous solution (1050 mL). The organic layer was separated and 2 SO 4 Drying and evaporation gave compound (2) as an oil (160 g, 88%). 1HNMR (CDCl 3 ,500MHz): δ4.26(dd,4H),2.55(s,1H),2.14(s,6H).
[0152] Preparation of 2-ethynyl-propane-1,2,3-triol (3)
[0153] Method B:
[0154]
[0155] To a solution of 2-ethynyl-2-hydroxypropane-1,3-diester diacetate (2) (70 g, 350 mmol) in ethanol was added a 0.5 M solution of sodium methoxylate in methanol (69.9 mL, 35.0 mmol) at room temperature (rt). The reaction was stirred at room temperature for 2 hours (h) to reach completion. The solvent was evaporated and the residue was redissolved in 100 mL of water and extracted with 3×50 mL of MTBE. The aqueous layer was bubbled with nitrogen to remove residual solvent to give a 40.9% solution of 2-ethynyl-propane-1,2,3-triol (3) as determined by nuclear magnetic resonance (NMR) (maleic acid as internal standard) (108 g, 100% yield). 1 HNMR (D 2 O,500MHz): δ3.60(dd,4H),2.85(s,1H).
[0156] Alternative preparation of (R)-2-ethynyl-glyceraldehyde (4)
[0157] Method C1:
[0158]
[0159] In a stirred reactor, 2-ethynyl-propane-1,2,3-triol (3) (1.1 g, 9.47 mmol) in sodium phosphate buffer (30 mL, 100 mM, pH 7.0) containing antifoam 204 (Sigma A6426, 1 drop ~ 20 μL) was warmed to 30°C under 12.5 sccm of air bubbling. Galactose oxidase (GOase, SEQ ID NO.: 1) (250 mg), horseradish peroxidase* (Type I, 5 mg) and bovine catalase** (5 mg) dissolved in sodium phosphate buffer (5 mL 100 mM, pH 7.0) were added to the reactor, followed by the addition of CuSO 4 Aqueous solution (100 mM, 150 μL). The reaction mixture was stirred at 600 rpm for 47 h under air bubbling to give (R)-2-ethynyl-glyceraldehyde (4) with 47% conversion (via NMR) and 72% ee. (The product was not isolated). 1HNMR (D 2 O,500MHz): δ4.29(s,1H),3.65(dd,2H),2.83(s,1H).
[0160] *Horseradish peroxidase: Wild-type peroxidase from type I horseradish, commercially available from SIGMA (P8125), isolated from horseradish root (Amoracia rusticana).
[0161] **Bovine Catalase: Heme-dependent catalase from bovine origin, commercially available from Sigma (C1345).
[0162] Method C2:
[0163]
[0164] In a stirred 100 L jacketed reactor filled with deionized water (56.2 kg), sodium dihydrogen phosphate (1.212 kg, 10 moles) was added. The pH was adjusted to 7.02 using 10 N sodium hydroxide solution (852.6 g) at 25 °C. Defoamer 204 (A6426, 10 mL) was charged to the reactor, followed by CuSO 4 ·5H 2 O (6.5 g). Galactose oxidase (451.2 g) (SEQ ID NO.: 10) was added and stirred for 15 min while bubbling with air. Horseradish peroxidase* (200.2 g) and catalase** (502.6 g) were added and the reactor was rinsed with water (2.0 kg). Next, an aqueous solution of 2-ethynyl-propane-1,2,3-triol (3) (9.48%, 30.34 kg, 24.72 mol) was added, followed by another portion of defoamer 204 (A6426, 10 mL). The reaction was bubbled with air and stirred overnight to give 94.0 kg of (R)-2-ethynyl-glyceraldehyde (4) with a conversion of 66% (via NMR) and 84% ee and an assay yield of 60%: 1 H NMR (D 2 O,500MHz): δ4.29(s,1H),3.65(dd,2H),2.83(s,1H).
[0165] *Horseradish peroxidase: Purified wild-type peroxidase from horseradish, commercially available from Toyobo (PEO-301), isolated from horseradish (Amoracia rustican).
[0166] **Bovine Catalase: Heme-dependent catalase from bovine origin, commercially available from Sigma (C1345).
[0167] The above reaction was also performed using galactose oxidase (SEQ ID NO.: 11) and the product (4) was obtained with 67% conversion (via NMR) and 88% ee and 59% assay yield: 1 H NMR (D 2 O,500MHz): δ4.29(s,1H),3.65(dd,2H),2.83(s,1H).
[0168] Method C3:
[0169]
[0170] In a 100 mL EasyMax container equipped with a bubbler and flow controller, water (82 mL) and PIPES potassium buffer (5 mL, 0.5 M) were charged. The pH was adjusted to 7.5 using 5 M KOH solution at 25°C. Defoamer 204 (200 μL) was added, followed by the evolved galactose oxidase (SEQ ID NO.: 17, 450 mg enzyme powder) and copper (II) sulfate pentahydrate (100 μL, 100 mM). The reaction mixture was bubbled with air at 125 standard cubic centimeters per minute (sccm) for 15 min. Bovine catalase (C1345, Sigma-Aldrich, 150 mg, 2000-5000 U / mg, 0.75 MU) was charged, followed by horseradish peroxidase (HRP, Toyobo PEO-301, 100 mg, 130 U / mg, 1.3 kU) and an aqueous solution of 2-ethynyl-propane-1,2,3-triol (3) (25 wt%, 12 mL, 25.8 mmol). The reaction mixture was stirred at 30° C. with aeration of 125 sccm and sampled every 20 h using EasySampler to obtain 70% conversion and form compound (4) ((R)-2-ethynyl-glyceraldehyde) in an assay yield of 58% and 99% ee. 1 HNMR (D 2 O, 500 MHz): δ 4.29 (s, 1H), 3.65 (dd, 2H), 2.83 (s, 1H). The crude reaction stream was directly taken to the subsequent phosphorylation step.
[0171] Method C4: Oxidation with immobilized galactose oxidase
[0172]
[0173] Enzyme immobilization procedure:
[0174] Nuvia IMAC nickel resin (16 mL, based on sedimentation volume) was added to a filter funnel and washed with binding buffer (10 column volumes, 160 mL; 500 mM sodium chloride, 50 mM sodium phosphate, 15 mM imidazole, pH 8.0) to remove the resin storage solution. In a container, the evolved galactose oxidase (SEQ ID NO.: 17, 2.00 g) lyophilized powder was resuspended in copper (II) sulfate solution (100 μM; 5.00 mL), followed by the addition of binding buffer (50 mL) and resin. The solution was mixed at 20° C. for 5 h using a rotary mixer. The resin was filtered and washed with binding buffer (10 column volumes, 160 mL) and PIPES potassium buffer (10 column volumes, 160 mL; 50 mM, pH 7.5), and used directly in the reaction.
[0175] Reaction procedure:
[0176] In a 100 mL EasyMax container equipped with a bubbler and flow controller, water (82 mL) and PIPES potassium buffer (5 mL, 1 M) were charged. The pH was adjusted to 7.5 at 25° C. using a 5 M KOH solution. Defoamer 204 (200 μL) was added, followed by the evolved galactose oxidase (SEQ ID NO.: 17, 750 mg enzyme powder per 6 mL resin) and copper (II) sulfate pentahydrate (100 μL, 100 mM) immobilized on the resin. The reaction mixture was bubbled with air at 125 standard cubic centimeters per minute (sccm) for 15 min. Bovine catalase (C1345, Sigma-Aldrich, 210 mg, 2000-5000 U / mg, 1.05 MU) was charged, followed by horseradish peroxidase (HRP, Toyobo PEO-301, 100 mg, 130 U / mg, 1.3 kU) and an aqueous solution of 2-ethynyl-propane-1,2,3-triol (3) (25 wt%, 13 mL, 29.4 mmol). The reaction mixture was stirred at 25 °C with aeration of 125 sccm. After 22 h, the reaction reached 91% conversion to give a 200 mM solution of (R)-2-ethynyl-glyceraldehyde (4) (100 mL, 68% assay yield, 97% ee). 1 HNMR (D 2 O, 500 MHz): δ 4.29 (s, 1H), 3.65 (dd, 2H), 2.83 (s, 1H). The crude reaction stream was directly taken to the subsequent phosphorylation step.
[0177] Method C5: Optional Isolation of Aldehyde by Formation of Aminal (8)
[0178] Step 1: Preparation of (S)-2-(1,3-dibenzylimidazolidin-2-yl)but-3-yne-1,2-diol
[0179]
[0180] A 100 L jacketed cylindrical vessel equipped with a nitrogen bubbler, mechanical stirrer, and thermocouple was charged with a crude oxidase reaction stream containing (R)-2-ethynyl-glyceraldehyde ((4), 26.0 kg, 1.85 wt% aldehyde, 3.64 mol) and heated with N 2 The atmosphere was inerted. The aqueous solution was warmed to 20°C and N,N-dimethyl dodecan-1-amine oxide (DDAO) (30 wt%, in water, 798 g, 0.96 mol) was added, followed by MTBE (55.3 kg, 76 L) and N,N'-dibenzylethane-1,2-diamine (1.55 kg, 6.43 mol). The brown two-phase mixture was stirred overnight at 20°C under a nitrogen atmosphere. After 17 hours, stirring was stopped, and the organic phase was removed and discarded. A light brown MTBE solution of (S)-2-(1,3-dibenzylimidazolidine-2-yl)but-3-yn-1,2-diol was obtained (56.5 kg, 2.02 wt% aminal, 3.39 mmol, 93% assay yield).
[0181] Six similar MTBE solutions (total 374.4 kg solution containing 7.91 kg aminal) were processed together in a single distillation and crystallization step.
[0182] A 50L jacketed cylindrical vessel equipped with a mechanical stirrer, a distillation head (condenser, at -20°C) and a thermocouple was charged with the aminal solution (45L). A vacuum (65–95 Torr) was applied to the vessel, and the jacket was set to 40°C. The solvent was removed by distillation until a volume of 35L was reached. At this point, the internal temperature was 6.1°C, and an off-white solid began to crystallize. The remaining MTBE solution was slowly added, maintaining a constant volume of 35-40L and an internal temperature of 0-10°C. Once all the MTBE solution had been added, the volume was reduced to 25L. The distillation was stopped, the vessel was inerted with nitrogen, and the jacket temperature was reduced to 10°C. The resulting pale yellow suspension was aged at this temperature for 2 hours, and the solid was collected by filtration. The filter cake was washed with cold (-2°C) MTBE (12.7kg) and then dried under a stream of nitrogen for 7 hours. (S)-2-(1,3-Dibenzylimidazolidin-2-yl)-but-3-yne-1,2-diol was obtained as an off-white crystalline solid (5.75 kg). 1 H NMR (500 MHz, DMSO-d 6)δ7.42–7.35(m,4H),7.32(td,J=7.5,1.6Hz,4H),7.27–7.21(m,2H),5.10(t,J=5.6Hz,1H),5.03(s,1H),4.28(d,J=13.3Hz ,1H),4.16(d,J=13.3Hz,1H),3.76(s,1H),3.70–3.58(m,4H),3.21(d,J=0.9Hz,1H),2.90–2.80(m,2H),2.60–2.51(m,2H). 13 C NMR (126 MHz, DMSO-d 6 )δ140.0,140.0,128.5,128.3,128.2,128.1,126.8,126.8,88.6,86.9,75.0,74.0,66.4,60.7,60.5,50.4,50.3,39.5.HR-MS(ESI)Aminal(M+H + )C 21 H 25 N 2 O 2 + Calculated value: 337.1911; measured value: 337.1922.
[0183] Step 2: Preparation of (R)-2-ethynyl-glyceraldehyde (4) from aminal (8)
[0184]
[0185] A 4 L jacketed cylindrical vessel equipped with a nitrogen bubbler and a mechanical stirrer was charged with TsOH·H 2 O (12.0 g, 63.1 mmol), water (60 mL), (S)-2-(1,3-dibenzylimidazolidin-2-yl)but-3-yn-1,2-diol (110 g, 327 mmol) and MTBE (1700 mL). The two-phase mixture was placed under nitrogen and the jacket temperature was set to 15°C. TsOH·H was added dropwise over 1.5 hours with overhead stirring (200 rpm). 2 O (114 g, 599.3 mmol) in water (600 mL). After the addition was complete, the jacket temperature was lowered to 5 °C and the resulting slurry was aged for 1 hour. The solids were removed by filtration and washed with cold water (270 mL). The two-phase solution was transferred to a separatory funnel and the organic phase was removed and discarded. TM MARATHON TM A resin (hydroxide form, 11.0 g) and 15 resin (hydrogen form, 11.0 g) was added to the aqueous phase and N 2 The residual MTBE was removed by bubbling for 24 hours. The resin was removed by filtration to give a colorless aqueous solution of (R)-2-hydroxy-2-(hydroxymethyl)but-3-ynal (774 g, 4.6 wt% aldehyde, 82% yield). 1 HNMR (500MHz, D 2 O) δ5.01(s,1H),3.77(d,J=11.7Hz,1H),3.73(d,J=11.7Hz,1H),2.92(s,1H). 13 CNMR(126MHz,D 2 O)δ129.4,125.4,90.3,81.0,76.0,73.9,65.3. HRMS (ESI) aldehyde dimer (2M+Na + )C 10 H 12 NaO 6 + Calculated value: 251.0526; measured value: 251.0530.
[0186] Alternative preparation of (R)-2-ethynyl-glyceraldehyde 3-phosphate (5):
[0187] Method D1: Acetate kinase: ATP regeneration system
[0188]
[0189] In a stirred reactor, to a solution of adenosine diphosphate disodium salt (40 mg, 0.087 mmol) and magnesium chloride (38 mg, 0.400 mmol) in HEPES buffer (66 mM, pH 7.5, 30 mL) was added (R)-2-ethynyl-glyceraldehyde (4) (1.9 mL, 210 g / L aqueous solution, 3.51 mmol), followed by acetate kinase (SEQ ID NO.: 3) (40 mg) and pantothenate kinase (SEQ ID NO.: 2) (120 mg). The reaction mixture was warmed to 25°C and a solution of lithium acetylphosphate potassium salt (1.3 g, 7.01 mmol) in HEPES buffer (50 mM, pH 7.5, 10 mL) was added dropwise over 4 hours, wherein the pH was maintained at 7.5 using 5 M sodium hydroxide. The reaction was stirred for 18 hours to give (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) (unisolated product) at 85% conversion (via HPLC). 1 H NMR (D 2 O,400MHz): δ5.02(s,1H),4.00(dq,2H),2.88(s,1H). LC-MS:(ES,m / z):C5 H 7 O 6 P(M - H) calculated: 193.1; found: 193.0.
[0190] Method D2: Pyruvate Oxidase ATP Regeneration System
[0191]
[0192] In a stirred reactor, to a solution of sodium pyruvate (3.11 g, 28 mmol) and phosphoric acid (0.523 mL, 7.71 mmol) in 76 mL of water pH 7.5 was charged (R)-2-ethynyl-glyceraldehyde (4) (3.8 mL, 210 g / L aqueous solution, 7.01 mmol), adenosine diphosphate disodium salt (80 mg, 0.174 mmol), thiamine pyrophosphate (40 mg, 0.086 mmol), flavin adenine dinucleotide disodium salt hydrate (64 mg, 0.077 mmol) and magnesium chloride (400 μL, 1 M aqueous solution, 0.4 mmol). The pH was readjusted to 7.5 with 5 M aqueous sodium hydroxide solution and the reaction volume was readjusted to 80 mL with water. Acetate kinase (SEQ ID NO.: 3) (80 mg), pyruvate oxidase (SEQ ID NO.: 4) (80 mg, lyophilized cell-free extract), pantothenate kinase (SEQ ID NO.: 2) (400 mg) and catalase (800 μL, ammonium sulfate suspension CAT-101, Biocatalytics) were added. The reaction was stirred at 500 rpm and 30° C. for 72 hours under air bubbling to give (R)-2-ethynyl-glyceraldehyde 3-phosphate 5 (unisolated product) with 95% conversion (via HPLC). 1 HNMR (D 2 O,400MHz): δ5.02(s,1H),4.00(dq,2H),2.88(s,1H). LC-MS:(ES,m / z):C 5 H 7 O 6 P(M - H) calculated: 193.1; found: 193.0.
[0193] The above reaction was also carried out using pantothenate kinase (SEQ ID NO.: 13), and product 5 was obtained at a conversion rate of 66%. (The product was not isolated). 1 HNMR (D 2 O,400MHz): δ5.02(s,1H),4.00(dq,2H),2.88(s,1H).
[0194] Method D3: Acetate kinase: ATP regeneration system using immobilized enzyme
[0195]
[0196] Enzyme immobilization procedure:
[0197] NUVIA TM Immobilized metal ion affinity chromatography (IMAC) nickel resin (168 mL, based on sedimentation volume) was added to a filter funnel and washed with binding buffer (1.6 L; 500 mM sodium chloride, 50 mM sodium phosphate, pH 8.0). In a container, pantothenate kinase (8.4 g) (SEQ ID NO.: 12) and acetate kinase (2.8 g) (SEQ ID NO.: 3) were dissolved in binding buffer (500 mL). The washed resin was loaded into a container and the solution was stirred at 20° C. for 4 hours. The resin was filtered and washed first with binding buffer (1.6 L) and then with piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES) buffer (840 mL; 50 mM, pH 6.5). The washed resin was used directly in the next step.
[0198] Reaction procedure:
[0199] A 1 L reactor was charged with a solution of (R)-2-ethynyl-glyceraldehyde (4) in water (608.7 g, 4.6 wt%, 212 mmol) and cooled to 5°C. Piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES) buffer (32.7 mL, 1 M, pH 6.5, 32.7 mmol), magnesium chloride (9.33 mL, 1 M, 9.33 mmol), acetylphosphate diammonium salt (51.8 g, 265 mmol), adenosine diphosphate disodium salt hydrate (1.17 g, 2.12 mmol) and water (192 mL) were added to the cooled solution. The solution was stirred and the pH was adjusted to 6.4 using 5N KOH. The reaction was warmed to 20°C and 168 mL of resin with co-immobilized pantothenate kinase (SEQ ID NO.: 12) and acetate kinase (SEQ ID NO.: 3) were added. The reaction was stirred with 5N KOH (used to maintain pH 6.4) for 10 hours and the product was obtained with 92% conversion (via HPLC) and 91% yield (via 31 P NMR with tetraphenylphosphonium chloride as internal standard) afforded (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) (unisolated product). 1 HNMR (D 2 O,400MHz): δ5.02(s,1H),4.00(dq,2H),2.88(s,1H). LC-MS:(ES,m / z):C 5 H7 O 6 P(M - H) calculated: 193.1; found: 193.0.
[0200] Preparation of 4-ethynyl-D-2-deoxyribose 5-phosphate (6)
[0201] Method E:
[0202]
[0203] To a solution of (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) (5, 20 mL, 5.3 mmol) in water was added a solution of acetaldehyde in water (40 wt.%, 2.02 mL, 15.9 mmol) at room temperature, followed by a solution of 25 mg of deoxyribose phosphate aldolase (DERA) (SEQ ID NO.: 6) in triethanolamine hydrochloride buffer (1 mL, 1 M, pH 7.0). The reactor was sealed and the mixture was stirred at 30°C and 600 rpm overnight to give 4-ethynyl-D-2-deoxyribose 5-phosphate (6) as a 1:1 anomer mixture at 99% conversion and 99% ee, 99% de (unseparated product). α-anomer: 1 HNMR (D 2 O,600MHz) δ5.31(t,1H),4.13(t,1H),3.81-3.72(m,2H),2.89(s,1H),2.42-2.34(m,1H),1.87-1.79(m,1H); 13 C NMR (D 2 O, 151MHz)δ97.7(s),81.4(d),79.4(s),78.9(s),71.1(s),67.7(d),39.6(s). β-anomer: 1 H NMR (D 2 O,600MHz) δ5.40(dd,1H),4.28(t,1H),3.88-3.80(m,2H),2.87(s,1H),2.13-2.06(m,1H),2.04-1.97(m,1H); 13 C NMR (D 2 O,151MHz) δ97.3(s),82.2(d),78.7(s),78.5(s),71.3(s),68.4(d),39.6(s). LC-MS:(ES,m / z):C 7 H 10 O 7 P(MH) calcd. 237.0; found 237.0.
[0204] Alternative preparation of (2R,3S,5R)-5-(6-amino-2-fluoro-9H-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol monohydrate (7) [alternative name 4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA]
[0205] Method F1:
[0206]
[0207] (((2R,3S)-2-ethynyl-3,5-dihydroxytetrahydrofuran-2-yl)methylammonium hydrogen phosphate (1.00 g, 3.91 mmol) was dissolved in 10 mL of pH 7.5 buffer (containing 5 mM MnCl 2 100mM triethanolamine·HCl). The pH of the solution was adjusted to 7.3 with 5NNaOH. 2-Fluoroadenine (0.599g, 3.91mmol) and sucrose (2.68g, 7.82mmol) were added to the solution. The enzyme solution was prepared by dissolving pentose phosphate mutase (SEQ ID NO.: 8) (100mg), purine nucleoside phosphorylase (SEQ ID NO.: 9) (50mg) and sucrose phosphorylase (SEQ ID NO.: 7) (10mg) in 10mL of pH 7.5 buffer. The enzyme solution was added to the reagent mixture and the resulting suspension was shaken at 40°C. After 20h, the suspension was cooled to 0°C and filtered, and rinsed with cold water. The solid was sucked dry to obtain the title compound (1.12g, 92%) as a single isomer.
[0208] 1 H NMR: (300MHz, DMSO-d6, ppm): δ7.68(br s,2H),7.32(d,J=2.0Hz,1H),6.44(t,J=5.8Hz,1H),5.52(d,J=5.6Hz,1H),5.27(t,J=6.0Hz,1H),4.44(q,J= 6.4Hz,1H),3.60(q,J=6.0Hz,1H),3.53(q,J=6.4Hz,1H),3.48(s,1H),2.48-2.41(m,1H),2.37-2.30(m,1H). 13C NMR (150.92MHz, DMSO-d6, ppm) δ158.5 (d, JCF = 203.5), 157.6 (d, JCF = 21.2), 150.2 (d, JCF = 20.2), 1 39.7 (d, JCF = 2.4), 117.4 (d, JCF = 4.0), 85.1, 82.0, 81.4, 78.7, 70.1, 64.2, 38.1. LC-MS: (ES, m / z): C 12 H 12 FN 5 O 3 Calculated for (M+Na): 316.0822; found 316.0818.
[0209] The PPM and PNP enzymes used in this step are each derived from mutations starting from an enzyme from Escherichia coli. The sucrose phosphorylase (SP) used in this step is derived from Alloscardovia omnicolens; SP derived from other organisms may also be used.
[0210] Method F2:
[0211]
[0212] To an aqueous solution of (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) (950 mL, 157 mmol) containing piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES) buffer at a pH of about 5.5 to 6.0 was added triethanolamine (7.09 g, 47.5 mmol). The pH of the solution was adjusted from 7.1 to 7.6 using potassium hydroxide (8 mL, 8 M). Manganese (II) chloride hydrate (0.592 g, 4.70 mmol) was added followed by sucrose (161 g, 470 mmol) to give a pH of 7.5. To this solution were added the following enzymes: deoxyribose phosphate aldolase (SEQ ID NO.: 14) (461 mg), sucrose phosphorylase (SEQ ID NO.: 7) (494 mg), pentose phosphate mutase (SEQ ID NO.: 8) (2.63 g), and purine nucleoside phosphorylase (SEQ ID NO.: 15) (659 mg). Once the enzyme is dissolved, 2-fluoroadenine (19.80 g, 125 mmol) is added. The reaction is heated to 35 ° C, and acetaldehyde (40 wt% in isopropanol, 29.8 mL, 235 mmol) is added. After 2 h of reaction, the mixture is seeded with EFdA crystallized product (0.96 g, 2 mol%). After 26 h of reaction at 35 ° C, the slurry is cooled to 0 ° C, and the solid is collected by filtration and washed twice with water (40 mL each time). The solid is dried under nitrogen purge. Yield 43.2 g, 92 wt%, corrected 96.2%. 1 H NMR: (300MHz, DMSO-d6, ppm): δ7.68(brs,2H),7.32(d,J=2.0Hz,1H),6.44(t,J=5.8Hz,1H),5.52(d,J=5.6Hz,1H),5.27(t,J=6. 0Hz,1H),4.44(q,J=6.4Hz,1H),3.60(q,J=6.0Hz,1H),3.53(q,J=6.4Hz,1H),3.48(s,1H),2.48-2.41(m,1H),2.37-2.30(m,1H). 13 C NMR (150.92MHz, DMSO-d6, ppm) δ158.5 (d, JCF = 203.5), 157.6 (d, JCF = 21.2), 150.2 (d, JCF = 20.2), 1 39.7 (d, JCF = 2.4), 117.4 (d, JCF = 4.0), 85.1, 82.0, 81.4, 78.7, 70.1, 64.2, 38.1. LC-MS: (ES, m / z): C 12 H 12 FN 5 O 3Calculated for (M+Na): 316.0822; found 316.0818.
[0213] Alternative preparation of (S)-2-ethynyl-propane-1,2,3-triol l1-phosphoric acid (9):
[0214] Method G1: Acetate kinase: ATP regeneration system using enzymes SEQ.ID No.: 2 and SEQ.ID No.: 3
[0215]
[0216] A 50 mL reactor was charged with a solution of 2-ethynyl-propane-1,2,3-triol (3) in water (9.29 g, 9.46 wt%, 7.57 mmol), PIPES potassium buffer (1.02 mL, 1 M, pH 6.5, 1.02 mmol), magnesium chloride (292 μL, 1 M, 0.292 mmol), acetyl phosphate diammonium salt (1.851 g, 89 wt%, 9.46 mmol), adenosine diphosphate disodium salt hydrate (ADP, 42 mg, 0.076 mmol, 0.01 eq) and water (28 mL). The pH was adjusted to 6.4 using 5 M KOH, the solution was warmed to 20° C., and the evolved pantothenate kinase PanK SEQ. ID NO.: 2 (264 mg) and acetate kinase AcK SEQ. ID No.: 3 (88 mg) were added. The reaction was stirred for 16 hours, with the pH maintained at 6.4 using 5 N KOH. The final reaction contents were >95% ee and 99% conversion (via 31 P NMR) afforded (S)-2-ethynyl-propane-1,2,3-triol 1-phosphoric acid (9). The product was not isolated. 1 H NMR (D 2 O,500MHz) δ3.89(m,2H),3.72(d,J=11.6Hz,1H),3.65(d,J=11.6Hz,1H),2.93(s,1H). 13 CNMR(D 2 O, 126MHz) δ 82.9 (s), 75.1 (s), 71.0 (d, J = 6.9Hz), 67.0 (d, J = 4.5Hz), 64.7 (s). 31PNMR(D 2 O,202MHz)δ3.39.HRMS:(ESI,m / z):[M-1] - C 5 H 8 O 6 Calculated value of P: 195.0058; Measured value: 195.0068 [MH] - :195.0058.
[0217] Method G2: Acetate kinase: ATP regeneration system using enzyme SEQ.ID No.: 20 and enzyme SEQ.ID No.: 21
[0218]
[0219] A jacketed reactor was charged with an aqueous solution of 2-ethynyl-propane-1,2,3-triol (3) (11.47 kg, 8.7% wt, 8.61 mol) and water (7.5 kg), followed by 1 M BIS-TRIS methane buffer pH 6.5 (1 L) and magnesium chloride (41.4 g). ATP (48 g, 0.086 mol, 0.01 equiv) and acetyl diammonium phosphate (2.021 kg, 89%, 10.33 mmol) were added, the solution was warmed to 20°C, and the pH of the solution was readjusted to 6.8 using KOH (270.4 g). Evolved pantothenate kinase SEQ.ID NO.: 20 (20.4 g) and evolved acetate kinase SEQ.ID No.: 21 (3 g) were then charged as solids. The reaction was stirred at 20°C for 16 h, during which time the pH dropped to 5.5. As determined by 1 Quantitative conversion of 2-ethynyl-propane-1,2,3-triol (3) was obtained as judged by H and 31P NMR. The (S)-2-ethynyl-propane-1,2,3-triol 1-phosphoric acid (9) solution (397 mM, 22.5 kg, 98% yield) thus prepared was used in the subsequent oxidation step without any further purification. 1 HNMR (D 2 O,500MHz) δ3.89(m,2H),3.72(d,J=11.6Hz,1H),3.65(d,J=11.6Hz,1H),2.93(s,1H).
[0220] Method G3: Acetate kinase: ATP regenerating system using enzyme SEQ. ID No.: 20 and enzyme SEQ. ID No.: 21 with deuterated compound (3) to assign absolute stereochemistry and confirm desymmetric phosphorylation.
[0221]
[0222] Evolved pantothenate kinase SEQ.ID NO.: 20 (100 μL of 10 g / L aqueous solution) and evolved acetate kinase SEQ.ID No.: 21 (100 μL of 2 g / L aqueous solution) were added to a solution containing acetyl diammonium phosphate (41 mg), 2-ethynyl-propane-1,1-d2-1,2,3-triol ((R)-3-d2, 20 mg, 170 μmol), magnesium chloride (10 μL of 1 M aqueous solution), ADP (10 μL of 100 g / L aqueous solution) and sodium phosphate buffer (10 μL of 1 M aqueous solution) in water (800 μL) (pH 6.5). The reaction was incubated at room temperature for 24 h to afford the deuterated 2-ethynyl-propane-1,2,3-triol 1-phosphate analogs (S)-9-(3,3-d2) and (S)-9-(1,1-d2) in a 95:5 ratio and 99% overall yield. 31 PNMR determined the ratio of the phosphorylated compounds to be ∼95:5, confirming the stereoselective phosphorylation of 2-ethynyl-propane-1,2,3-triol (3) at the front (S) hydroxyl group (i.e., desymmetric phosphorylation). 1 HNMR (D 2 O,500MHz) δ3.89(m,2H),3.72(d,J=11.6Hz,1H),3.65(d,J=11.6Hz,1H),2.93(s,1H). 13 C NMR (D 2 O, 126MHz) δ 82.9 (s), 75.1 (s), 71.0 (d, J = 6.9Hz), 67.0 (d, J = 4.5Hz), 64.7 (s).
[0223] Method G4: Acetate kinase: ATP regeneration system using immobilized enzyme SEQ.ID No.: 20 and enzyme SEQ.ID No.: 21
[0224]
[0225] Enzyme immobilization procedure:
[0226] Nuvia IMAC nickel resin (75 mL, based on sedimentation volume) was added to a filter funnel and washed with water (9 column volumes, 3×225 mL) and binding buffer (1 column volume, 75 mL; 500 mM sodium chloride, 50 mM sodium phosphate, 15 mM imidazole, pH 8.0). In a container, lyophilized pantothenate kinase (SEQ ID NO.: 20, 6.0 g) was resuspended in binding buffer (200 mL) and the washed resin was added. The solution was mixed at 25° C. for 6 h using a rotary mixer. The resin was filtered and washed with binding buffer (6 column volumes, 6×225 mL) and BIS-TRIS buffer (8 column volumes, 600 mL; 50 mM, pH 6.2).
[0227] Reaction procedure:
[0228] An aqueous solution of 2-ethynyl-propane-1,2,3-triol (3) (574 g, 8.7% wt, 0.430 mol) and water (350 mL) was charged into a jacketed reactor followed by 1 M BIS-TRIS methane buffer pH 6.5 (50 mL) and magnesium chloride (2.033 g, 0.01 mol). ATP (2.37 g, 0.0043 mol, 0.01 eq) and acetyl diammonium phosphate (101 g, 89%, 0.530 mmol, 1.2 eq) were added, the solution was warmed to 20 °C and the pH of the solution was readjusted to 6.8 using 5 M KOH. The resin with immobilized pantothenate kinase SEQ. ID NO.: 20 (25 mL) and evolved acetate kinase SEQ. ID No.: 21 (0.15 g) were then charged as solids. The reaction was stirred at 20 °C for 16 h during which time the pH dropped to 5.5. As determined by 1 H and 31 Quantitative conversion of 2-ethynyl-propane-1,2,3-triol (3) to (S)-2-ethynyl-propane-1,2,3-triol 1-phosphoric acid (9) was obtained as judged by P NMR. 1 H NMR (D 2 O,500MHz) δ3.89(m,2H),3.72(d,J=11.6Hz,1H),3.65(d,J=11.6Hz,1H),2.93(s,1H).
[0229] Alternative preparation of (R)-2-ethynyl-glyceraldehyde 3-phosphate (5)
[0230] Method H1: Immobilized galactose oxidase SEQ ID No.: 16
[0231]
[0232] Enzyme immobilization procedure:
[0233] Nuvia IMAC nickel-bearing resin (10 mL, based on sedimentation volume) was added to a filter funnel and washed with binding buffer (10 column volumes, 100 mL; 500 mM sodium chloride, 50 mM sodium phosphate, 15 mM imidazole, pH 8.0) to remove the resin storage solution and obtain 16 g of washed resin. In a container, the evolved galactose oxidase (SEQ ID NO.: 16, 750 mg) lyophilized powder was resuspended in copper (II) sulfate solution (100 μM; 5.00 mL), followed by the addition of binding buffer (20 mL) and washed resin (3.0 g). The solution was mixed at 20° C. for 5 h using a rotary mixer. The resin was filtered and washed with binding buffer (10 column volumes, 100 mL) and BIS-TRIS buffer (10 column volumes, 100 mL; 50 mM, pH 7.5), and used directly in glycosylation reactions.
[0234] Reaction procedure:
[0235] The resin (3.0 g) with immobilized galactose oxidase SEQ ID NO.: 16 was added to a solution of (S)-2-ethynyl-propane-1,2,3-triol 1-phosphate (9, 5.4 mmol, 270 mM, 20 mL) in BIS-TRIS methane buffer (35 mM, pH adjusted to 7.2), followed by addition of aqueous copper (II) sulfate solution (30 μL, 100 mM) and horseradish peroxidase (PEO-301, 18 mg) and bovine catalase (C1345, 120 mg) resuspended in water (600 μL). The reaction was sealed with a gas permeable membrane and vigorously shaken at 22° C. for 4 days to achieve a final conversion of 77% and to obtain (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) with 95% ee. The enzyme resin was filtered off and the solution of (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) was used directly in the glycosylation reaction. 1 HNMR (D 2 O,400MHz): δ5.02(s,1H),4.00(dq,2H),2.88(s,1H). LC-MS:(ES,m / z):C 5 H 7 O 6 P(M - H) calculated: 193.1; found: 193.0.
[0236] Method H2: Immobilized galactose oxidase SEQ ID No.: 17
[0237]
[0238] Enzyme immobilization procedure:
[0239] Nuvia IMAC nickel-bearing resin (10 mL, based on sedimentation volume) was added to a filter funnel and washed with binding buffer (10 column volumes, 100 mL; 500 mM sodium chloride, 50 mM sodium phosphate, 15 mM imidazole, pH 8.0) to remove the resin storage solution and obtain 16 g of washed resin. In a container, the evolved galactose oxidase (SEQ ID NO.: 16, 750 mg) lyophilized powder was resuspended in copper (II) sulfate solution (100 μM; 5.00 mL), followed by the addition of binding buffer (20 mL) and washed resin (3.0 g). The solution was mixed at 20° C. for 5 h using a rotary mixer. The resin was filtered and washed with binding buffer (10 column volumes, 100 mL) and BIS-TRIS methane buffer (10 column volumes, 100 mL; 50 mM, pH 7.5), and used directly in the reaction.
[0240] Reaction procedure:
[0241] The resin (3.0 g) with the immobilized evolved galactose oxidase SEQ ID NO.: 17 was added to a solution of (S)-2-ethynyl-propane-1,2,3-triol 1-phosphate (9, 5.4 mmol, 270 mM, 20 mL) in BIS-TRIS methane buffer (35 mM, pH adjusted to 7.2), followed by addition of aqueous copper (II) sulfate solution (30 μL, 100 mM) and horseradish peroxidase (PEO-301, 18 mg) and bovine catalase (C1345, 120 mg) resuspended in water (600 μL). The reaction was sealed with a gas permeable membrane and vigorously shaken at 22° C. for 4 days to achieve a final conversion of 77% and to obtain (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) with 95% ee. The enzyme resin was filtered off and the solution of (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) was used directly in the glycosylation reaction. 1 H NMR (D 2 O,400MHz): δ5.02(s,1H),4.00(dq,2H),2.88(s,1H). LC-MS:(ES,m / z):C 5 H 7 O 6 P(M - H) calculated: 193.1; found: 193.0.
[0242] Method H3: Immobilized galactose oxidase SEQ ID No.: 18
[0243]
[0244] Enzyme immobilization procedure:
[0245] Nuvia IMAC nickel-bearing resin (3 mL, based on sedimentation volume) was added to a filter funnel and washed with binding buffer (10 column volumes, 30 mL; 500 mM sodium chloride, 50 mM sodium phosphate, 15 mM imidazole, pH 8.0) to remove the resin storage solution and obtain 2.4 g of washed resin. The evolved galactose oxidase (SEQ ID NO.: 18, 75 mg) lyophilized powder was resuspended in copper (II) sulfate solution (100 μM; 1.00 mL) in a vial, followed by addition of binding buffer (5 mL) and washed resin (400 mg). The solution was mixed at 20° C. for 5 h using a rotary mixer. The resin was filtered and washed with binding buffer (10 column volumes, 4 mL) and BIS-TRIS methane buffer (10 column volumes, 4 mL; 50 mM, pH 7.5), and used directly in the reaction.
[0246] Reaction procedure:
[0247] Immobilized evolved GOase SEQ ID NO.: 18 (400 mg) was added to a solution of (S)-2-ethynyl-propane-1,2,3-triol 1-phosphoric acid solution ((9), 5.4 mmol, 270 mM, 1 mL) in BIS-TRIS methane buffer (35 mM, pH adjusted to 7.2), followed by horseradish peroxidase (PEO-301, 1 mg) and catalase (Roche, lyophilized product, #11650645103, 3 mg) resuspended in water (100 μL). The reaction was sealed with a gas permeable membrane and vigorously shaken at 30° C. for 48 h. After 2 days, the final conversion rate reached 90% conversion rate and (R)-2-ethynyl-glyceraldehyde 3-phosphoric acid (5)>99% ee. The enzyme resin was filtered off and the solution of (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) was used directly without further purification. 1 H NMR (D 2 O,400MHz): δ5.02(s,1H),4.00(dq,2H),2.88(s,1H). LC-MS:(ES,m / z):C 5 H 7 O 6 P(M - H) calculated: 193.1; found: 193.0.
[0248] Method H4: Immobilized galactose oxidase SEQ ID No.: 19
[0249]
[0250] Enzyme immobilization procedure:
[0251] Nuvia IMAC nickel-bearing resin (3 mL, based on sedimentation volume) was added to a filter funnel and washed with binding buffer (10 column volumes, 30 mL; 500 mM sodium chloride, 50 mM sodium phosphate, 15 mM imidazole, pH 8.0) to remove the resin storage solution and obtain 2.4 g of washed resin. The evolved galactose oxidase (SEQ ID NO.: 19, 75 mg) lyophilized powder was resuspended in copper (II) sulfate solution (100 μM; 1.00 mL) in a vial, followed by addition of binding buffer (5 mL) and washed resin (400 mg). The solution was mixed at 20° C. for 5 h using a rotary mixer. The resin was filtered and washed with binding buffer (10 column volumes, 4 mL) and BIS-TRIS methane buffer (10 column volumes, 4 mL; 50 mM, pH 7.5), and used directly in the reaction.
[0252] Reaction procedure:
[0253] Immobilized evolved GOase SEQ ID NO.: 18 (400 mg) was added to (S)-2-ethynyl-propane-1,2,3-triol 1-phosphoric acid solution (9,5.4 mmol, 270 mM, 1 mL) in a solution of BIS-TRIS methane buffer (35 mM, pH adjusted to 7.2), followed by addition of horseradish peroxidase (PEO-301, 1 mg) and catalase (Roche, lyophilized product, #11650645103, 3 mg) from Corynebacterium glutamicum that were resuspended in water (100 μ L). The reaction was sealed with a gas permeable membrane and vigorously shaken at 30° C. for 48 h. Final conversion reached 100% conversion after 2 days, and (R)-2-ethynyl-glyceraldehyde 3-phosphoric acid (5) was obtained with >99% ee. The enzyme resin was filtered off and the solution of (R)-2-ethynyl-glyceraldehyde 3-phosphate (5) was used directly without further purification. 1 H NMR (D 2 O, 400MHz): δ5.02 (s, 1H), 4.00 (dq, 2H), 2.88 (s, 1H). LC-MS: (ES, m / z): C 5 H 7 O 6 P(MH) calcd. 193.1; found 193.0.
[0254] "Amino acids" are referred to herein by any of their commonly known single-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. For the purposes of the description herein, the codes for the genetically encoded amino acids used in the enzymes used in the methods herein are conventional in Table 2:
[0255] Table 2
[0256] Amino Acids Single letter code Amino Acids Single letter code Alanine A Isoleucine I Arginine R Leucine L Asparagine N Lysine K Aspartic acid D Methionine M Asparagine or Aspartic Acid B Phenylalanine F Cysteine C Proline P Glutamate E Serine S Glutamine Q Threonine T Glutamine or Glutamate Z Tryptophan W Glycine G Tyrosine Y Histidine H Valine V .
[0257] Sequence ID numbers for enzymes used or that may be used in the processes for synthesizing EFdA described herein and in exemplary process steps in the experimental procedures described herein are provided, but are not limited to those in Table 3.
[0258] Table 3
[0259]
[0260]
[0261]
[0262]
[0263]
[0264]
[0265]
[0266]
[0267] Horseradish peroxidase: Wild-type peroxidase from type I horseradish, commercially available from SIGMA (P8125), isolated from horseradish (Amoracia rusticana).
[0268] Catalase: (1) wild-type catalase from bovine liver, commercially available from SIGMA (C1345); or (2) CAT-101, Biocatalytics; or (3) from Corynebacterium glutamicum (Roche, #11650645103).
[0269] Other embodiments of the present invention include, but are not limited to, the use of the following enzymes in the steps of the synthetic processes described herein to produce 4'-ethynyl 2'-deoxynucleosides or analogs thereof, such as EFdA.
[0270] A. Purine nucleoside phosphorylase.
[0271] 1A. An engineered purine nucleoside phosphorylase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO.: 9 or SEQ ID NO.: 15, or a functional fragment thereof, wherein the polypeptide sequence of the engineered purine nucleoside phosphorylase comprises at least one amino acid substitution or group of amino acid substitutions compared to SEQ ID NO.: 9 or SEQ ID NO.: 15.
[0272] 2A. The engineered purine nucleoside phosphorylase of 1A, wherein the engineered purine nucleoside phosphorylase comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to SEQ ID NO: 9 or SEQ ID NO.: 15.
[0273] 3A. An engineered purine nucleoside phosphorylase comprising the polypeptide sequence shown in SEQ ID NO:9 or SEQ ID NO.:15.
[0274] A4. The engineered purine nucleoside phosphorylase of any one of 1A to 3A, comprising at least one improved property compared to wild-type E. coli purine nucleoside phosphorylase.
[0275] 5A.4A engineered purine nucleoside phosphorylase, which is different from wild type Escherichia coli The improved properties compared to purine nucleoside phosphorylases include improved activity toward substrate compound 6.5 (in its cyclic form or as an open chain aldehyde or hydrate, or a salt of any of the foregoing).
[0276] 6A.4A engineered purine nucleoside phosphorylase, which is different from wild type Escherichia coli The improved properties include improved production of EFdA (Compound 7) compared to purine nucleoside phosphorylase.
[0277] 7A. The engineered purine nucleoside phosphorylase of any one of A1 to 6A, wherein the engineered purine nucleoside phosphorylase is purified.
[0278] 8A. The engineered purine nucleoside phosphorylase of any one of 1A to 7A, wherein the at least one amino acid substitution (ie, one or more amino acid substitutions) is a conservative amino acid substitution.
[0279] B. Pentose phosphate mutase.
[0280] 1B. An engineered pentosephosphomutase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 8, or a functional fragment thereof, wherein the polypeptide sequence of the engineered pentosephosphomutase comprises at least one amino acid substitution or group of amino acid substitutions compared to SEQ ID NO: 8.
[0281] 2B. The engineered pentose phosphate mutase of IB, wherein the engineered pentose phosphate mutase comprises a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to SEQ ID NO.: 8.
[0282] 3B. An engineered pentose phosphomutase comprising the polypeptide sequence shown in SEQ ID NO.:8.
[0283] 4B. The engineered pentose phosphate mutase of any one of 1B to 3B, which is different from the wild type Escherichia coli The invention relates to a novel phosphopentose mutase comprising at least one improved property compared to a phosphopentose mutase.
[0284] 5B.4B engineered pentose phosphomutase, which is different from the wild type Escherichia coli The improved properties compared to the pentose phosphate mutase include improved activity towards the substrate compound 6 (in its cyclic form or as an open chain aldehyde or hydrate, or a salt of any of the foregoing).
[0285] 6B.4B engineered pentose phosphomutase, which is different from the wild type Escherichia coli The improved properties include improved production of compound 6.5 or compound 7 (EFdA) compared to pentose phosphomutase.
[0286] 7B. The engineered pentose phosphomutase of any one of 1B to 6B, wherein the engineered pentose phosphomutase is purified.
[0287] 8B. The engineered pentose phosphomutase of any one of IB to 7B, wherein the at least one amino acid substitution (ie, one or more amino acid substitutions) is a conservative amino acid substitution.
[0288] C. deoxyribose phosphate aldolase.
[0289] 1C. A deoxyribose phosphate aldolase comprising the wild-type polypeptide sequence shown in SEQ ID NO: 5 from Shewanella halifax.
[0290] 2C. An engineered deoxyribose phosphate aldolase comprising the polypeptide sequence shown in SEQ ID NO.: 6 or SEQ ID NO.: 14.
[0291] 3C. An engineered deoxyribose phosphate aldolase, wherein the engineered deoxyribose phosphate aldolase comprises a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO.: 5, SEQ ID NO.: 6 or SEQ ID NO.: 14.
[0292] 4C. An engineered deoxyribose phosphate aldolase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO.: 5, SEQ ID NO.: 6 or SEQ ID NO.: 14, or a functional fragment thereof, wherein the polypeptide sequence of the engineered deoxyribose phosphate aldolase comprises at least one amino acid substitution or amino acid substitution group compared to SEQ ID NO.: 5, SEQ ID NO.: 6 or SEQ ID NO.: 14.
[0293] 5C. The deoxyribose phosphate aldolase of any one of 1C to 4C, which has activity on the substrate compound 5 ((R)-2-ethynyl-glyceraldehyde 3-phosphate, a hydrate thereof, or a salt of any one of the foregoing).
[0294] 6C. A deoxyribose phosphate aldolase according to any one of 1C to 5C, comprising the ability to produce compound 6 (4-ethynyl-D-2-deoxyribose 5-phosphate, or its open-chain aldehyde or hydrate form, or a salt of any one of the foregoing) during the reaction without the need for a protecting group on the substrate compound 5 ((R)-2-ethynyl-glyceraldehyde 3-phosphate, a hydrate thereof, or a salt of any one of the foregoing).
[0295] 7C. The engineered deoxyribose phosphate aldolase of any one of 2C to 6C, wherein the engineered deoxyribose phosphate aldolase is different from the wild type Halifax Shewanella The deoxyribose phosphate aldolase has improved properties compared to the deoxyribose phosphate aldolase, wherein the improved properties include improved production of compound 6 (4-ethynyl-D-2-deoxyribose 5-phosphate, or its open-chain aldehyde or hydrate form, or a salt of any of the foregoing).
[0296] 8C. The deoxyribose phosphate aldolase of any one of 1C to 7C, wherein the deoxyribose phosphate aldolase is purified.
[0297] 9C. The engineered deoxyribose phosphate aldolase of any one of 2C to 7C, wherein the at least one amino acid substitution (ie, one or more amino acid substitutions) is a conservative amino acid substitution.
[0298] D. Pantothenate kinase.
[0299] 1D. An engineered pantothenate kinase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2, SEQ ID NO.: 12, SEQ ID NO.: 13 or SEQ ID NO.: 20, or a functional fragment thereof, wherein the polypeptide sequence of the engineered pantothenate kinase comprises at least one amino acid substitution or group of amino acid substitutions compared to SEQ ID NO: 2, SEQ ID NO.: 12, SEQ ID NO.: 13 or SEQ ID NO.: 20.
[0300] 2D.1D's engineered pantothenate kinase, wherein the engineered pantothenate kinase comprises a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO.: 2, SEQ ID NO.: 12, SEQ ID NO.: 13 or SEQ ID NO.: 20.
[0301] 3D. An engineered pantothenate kinase comprising the polypeptide sequence shown in SEQ ID NO.: 2, SEQ ID NO.: 12, SEQ ID NO.: 13 or SEQ ID NO.: 20.
[0302] 4D. The engineered pantothenate kinase of any one of 1D to 3D, comprising at least one improved property compared to wild-type E. coli pantothenate kinase.
[0303] 5D. An engineered pantothenate kinase of 4D, wherein the improved property comprises improved activity towards substrate compound 4 ((R)-2-ethynyl-glyceraldehyde or a hydrate form thereof) compared to wild-type E. coli pantothenate kinase.
[0304] 6D. The engineered pantothenate kinase of 5D, wherein the improved property comprises improved production of compound 5 ((R)-2-ethynyl-glyceraldehyde 3-phosphate) compared to wild-type pantothenate kinase.
[0305] 7D. The engineered pantothenate kinase of 4D, wherein the improved property comprises improved activity towards substrate compound 3 (2-ethynyl-propane-1,2,3-triol) compared to wild-type E. coli pantothenate kinase.
[0306] 8D. The engineered pantothenate kinase of 7D, wherein the improved property comprises improved production of compound 9 ((S)-2-ethynyl-propane-1,2,3-triol 1-phosphate) compared to wild-type pantothenate kinase.
[0307] 9D. The engineered pantothenate kinase of any one of 1D to 8D, wherein the pantothenate kinase is purified.
[0308] 10D. The engineered pantothenate kinase of any one of 1D to 9D, wherein the at least one amino acid substitution (ie, one or more amino acid substitutions) is a conservative amino acid substitution.
[0309] E. Galactose oxidase.
[0310] 1E. An engineered galactose oxidase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NOs: 1, 10, 11, 16, 17, 18 or 19, or a functional fragment thereof, wherein the polypeptide sequence of the engineered galactose oxidase comprises at least one amino acid substitution or group of amino acid substitutions compared to SEQ ID NOs.: 1, 10, 11, 16, 17, 18 or 19.
[0311] 2E.1E's engineered galactose oxidase, wherein the engineered galactose oxidase comprises a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO.: 1, 10, 11, 16, 17, 18 or 19.
[0312] 3E. An engineered galactose oxidase comprising the polypeptide sequence shown in SEQ ID NO: 1, 10, 11, 16, 17, 18 or 19.
[0313] 4E. The engineered galactose oxidase of any of 1E to 3E, comprising at least one improved property compared to wild-type Fusarium graminearum galactose oxidase.
[0314] 5E. The engineered galactose oxidase of 4E, wherein the improved property comprises improved activity towards a substrate that is a primary alcohol compared to a wild-type Fusarium graminearum galactose oxidase.
[0315] 6E. The engineered galactose oxidase of 4E, wherein the improved property comprises improved activity towards substrate compound 3 (2-ethynyl-propane-1,2,3-triol) compared to wild-type Fusarium graminearum galactose oxidase.
[0316] 7E. The engineered galactose oxidase of 6E, wherein the improved property comprises improved production of compound 4 ((R)-2-ethynyl-glyceraldehyde or a hydrate form thereof) compared to wild-type Fusarium graminearum galactose oxidase.
[0317] 8E. The engineered galactose oxidase of 4E, wherein the improved property comprises improved activity towards substrate compound 9 ((S)-2-ethynyl-propane-1,2,3-triol 1-phosphate) compared to wild-type Fusarium graminearum galactose oxidase.
[0318] 9E. The engineered galactose oxidase of 8E, wherein the improved property comprises improved production of compound 5 ((R)-2-ethynyl-glyceraldehyde 3-phosphate or a hydrate form thereof) compared to wild-type Fusarium graminearum galactose oxidase.
[0319] 10E. The engineered galactose oxidase of any one of 1E to 9E, wherein the galactose oxidase is purified.
[0320] 11E. The engineered galactose oxidase of any one of 1E to 10E, wherein the at least one amino acid substitution (ie, one or more amino acid substitutions) is a conservative amino acid substitution.
[0321] F. Acetate kinase.
[0322] 1F. Acetate kinase comprising the wild-type polypeptide sequence shown in SEQ ID NO.: 3 or SEQ ID NO.: 21 from Thermotoga maritima.
[0323] 2F. An engineered acetate kinase, wherein the engineered acetate kinase comprises a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to SEQ ID NO.: 3 or SEQ ID NO.: 21.
[0324] 3F. An engineered acetate kinase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 3 or SEQ ID NO: 21, or a functional fragment thereof, wherein the polypeptide sequence of the engineered acetate kinase comprises at least one amino acid substitution or group of amino acid substitutions compared to SEQ ID NO.: 3 or SEQ ID NO: 21.
[0325] 4F. The acetate kinase of 2F or 3F, which comprises at least one improved property compared to wild-type Thermotoga maritima acetate kinase.
[0326] 5F. The acetate kinase of 4F, wherein the improved property comprises improved activity in ATP-cofactor recycling in the phosphorylation reaction of substrate compound 4 ((R)-2-ethynyl-glyceraldehyde or a hydrate form thereof) compared to wild-type Thermotoga maritima acetate kinase.
[0327] 6F. The acetate kinase of 5F, wherein the improved property comprises improved production of compound 5 ((R)-2-ethynyl-glyceraldehyde 3-phosphate or a hydrate form thereof or a salt of any of the foregoing) compared to wild-type Thermotoga maritima acetate kinase.
[0328] 7F. The acetate kinase of 4F, wherein the improved property comprises improved activity in ATP-cofactor recycling in the phosphorylation reaction of substrate compound 3 (2-ethynyl-propane-1,2,3-triol) compared to wild-type Thermotoga maritima acetate kinase.
[0329] 8F. The acetate kinase of 7F, wherein the improved property comprises improved production of compound 9 ((S)-2-ethynyl-propane-1,2,3-triol 1-phosphate or a salt of any of the foregoing) compared to wild-type Thermotoga maritima acetate kinase.
[0330] 9F. The acetate kinase of any one of 1F to 8F, wherein the acetate kinase is purified.
[0331] 10F. The engineered acetate kinase of any one of 2F to 7F, wherein at least one amino acid substitution (ie, one or more amino acid substitutions) is a conservative amino acid substitution.
Claims
1. A method for synthesizing compound 5 The method comprises treating compound 4 with pantothenate kinase in a buffered solution, In the presence of a divalent metal salt, In combination with ATP as the phosphate source, wherein the ATP is regenerated in situ, 2X + is (a) two protons, (b) a proton and a monovalent cation, (c) two monovalent cations, wherein each cation is the same or different, or (d) a divalent cation.
2. The method of claim 1, wherein ATP is regenerated in situ using (a) acetyl phosphate and acetate kinase, or (b) pyruvate oxidase, catalase and acetate kinase in the presence of pyruvate, phosphate and oxygen, or (c) a combination thereof.
3. The method of claim 2, wherein (a) the pantothenate kinase is immobilized or (b) the pantothenate kinase and the acetate kinase are immobilized.
4. A method for synthesizing compound 4 The method comprises treating compound 3 With galactose oxidase, copper, catalase and peroxidase or oxidant, and combined in a buffer solution in the presence of oxygen to produce compound 4.
5. The method of claim 4, wherein the galactose oxidase is immobilized.
6. A method for isolating compound 4 The method comprises (1) Compound 4 is reacted with an amine, diamine or amino alcohol that forms a stable N,N-acetal or N,O-acetal in an organic solvent that is immiscible with water, reacting in the absence of oxygen to form an aminal; and (2) reacting the aminal with an organic acid or an inorganic acid in the presence of an organic solvent immiscible with water to regenerate compound 4.
7. A method for synthesizing compound 5 The method comprises treating compound 9 With galactose oxidase in buffer solution, in combination in the presence of oxygen, catalase and either peroxidase or a chemical oxidant, To produce compound 5, 2X + is (a) two protons, (b) a proton and a monovalent cation, (c) two monovalent cations, wherein each of the cations is the same or different, or (d) a divalent cation.
8. A method for synthesizing compound 9 The method comprises treating compound 3 with pantothenate kinase in a buffered solution, In the presence of a divalent metal salt, In combination with ATP as the phosphate source, wherein the ATP is regenerated in situ, To produce compound (9), 2X + is (a) two protons, (b) a proton and a monovalent cation, (c) two monovalent cations, wherein each of the cations is the same or different, or (d) a divalent cation.
9. Compounds 10. Compounds 11. Compounds 2X + is (a) two protons, (b) a proton and a monovalent cation, (c) two monovalent cations, wherein each of the cations is the same or different, or (d) a divalent cation.
12. Compounds 2X + is (a) two protons, (b) a proton and a monovalent cation, (c) two monovalent cations, wherein each of the cations is the same or different, or (d) a divalent cation.
